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Introduction
Hyperhomocysteinemia (>15umol/L) is a recognised independent risk factor in the 
genesis of vascular diseases. There are few data on the relationship between 
homocysteine and abdominal aortic aneurysm (AAA), peripheral vascular disease 
(PVD), and the effect of vitamin B]2 and folic acid blood levels on plasma 
homocysteine concentration. This study was aimed to examine this possible 
relationship.
Method
Ethical approval was obtained for this case-control study. Fasting homocysteine blood 
levels were analysed using a fluorescence polarisation immunoassay technique. 
Serum vitamin Bn and folic acid was analysed using chemiluminescence detection 
technique. Serum was separated within one hour of blood collection from antecubital 
venous puncture into an EDTA primed tube, from 38 patients with AAA, 36 patients 
with PVD and 36 control subjects for analysis of homocysteine, vitamin Bi 2 and folic 
acid.
Results
Twenty-six (68%) patients with AAA and 26 (72%) patients with PVD patients had 
elevated levels of plasma homocysteine (>15umol/L) compared with 2 (6%) in the
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case controls. The mean homocysteine levels in the AAA, PVD and control groups 
were 19.4 ± SE 1.1 (95% CI 17.17 - 21.65), 18.4 ± SE 0.47 (95% CI 16.32 - 20.35) 
and 10.9 ± SE 1.0 umols/L (95% CI 9.95 - 11.88) respectively. The difference in 
mean levels of homocysteine in the AAA vs the control and the PVD vs control was 
statistically significant (P< 0.001). Mean vitamin Bn in the AAA, PVD and control 
groups was 332.11 ± SE 16.44 pg/L , 320.47 ± SE 16.81 pg/L and 414.33 + SE 19.72 
pg/L respectively. The difference in the mean levels of serum vitamin 812 in the AAA 
vs the control group and the PVD vs the control groups were statistically significant 
(P < 0.004). Mean serum folic acid for AAA, PVD and control was 8.02 ± SE 0.71 
r]gm /L , 7.84 ± SE 0.81 r|gm /L and 9.80 ± SE 0.69 t|gm /L respectively (P> 0.05). 
However, there was an inverse relationship between plasma homocysteine and B^ (r 
= -0.420, P = 0.000) and, plasma homocysteine and folic acid (r = -0.326, P = 0.001).
Conclusion
This study shows significantly higher levels of plasma homocysteine in patients with 
AAA and PVD in comparison to control. Use of supplemental vitamins that can lower 
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For more than 20 years, raised plasma total homocysteine (THcy) has been 
associated with risk of atherosclerotic and thrombotic event. In fact, it is now nearly 
40 years since attention was first drawn to the possible relationship of raised plasma 
homocysteine to premature vascular diseases in patients who suffered from 
homocysteinuria. Recently, evidence has mounted to suggest that the association may 
be causal. This association is independent of other known risk factors such as 
hypertension, hyperlipidemia, hypercholesterolemia, diabetes and smoking. The 
association is fairly consistent across many studies, is strong and dose-related, and is 
biologically plausible. Homocysteine is a sulphur containing amino acid, elevated 
plasma levels of which are referred to as hyperhomocysteinemia. It is an intermediary 
product in methionine metabolism. The transfer of methyl group from methionine is 
an important step in the metabolism of nucleic acids, fats, and high-energy bonds. 
When methionine donates its methyl group, homocysteine is formed. The majority of 
homocysteine is recycled in a transmethylation reaction involving vitamin 612 and 
folic acid while a smaller amount is metabolised by transulphuration involving 
vitamin B 6 . Hence the vitamin intake and serum vitamin levels play an important part 
in the regulation of plasma homocysteine levels. Whereas the stenotic lesions such as 
coronary artery disease (CAD), cerebrovascular disease (CVD) and peripheral 
vascular disease (PVD) and its correlation to plasma homocysteine has received much 
of the attention in scientific literature, there is very little data that on the relationship 
between hyperhomocysteinemia and arterial aneurysm. The pathology of the 
aneurysmal disorder is largely similar to stenotic lesion with the basic pathology 
being atherosclerosis. In addition, there are other factors such as serine elastase and 
matrix metalloproteinases that have an influence in the genesis of aneurysmal disorder
suggesting that there may be a genetic, biochemical and nutritional basis of elevated 
plasma homocysteine.
Annual mortality from peripheral vascular disease, and abdominal aortic 
aneurysm (AAA) in the U.K. is estimated to be more than 2,500 and about 6,000 per 
annum respectively (Office of Population Censuses and Surveys. 1995). Thus AAA 
and P VD are common vascular diseases. To prevent their development and arrest their 
progression by identification and reduction of risks such as lowering of plasma 
homocysteine would contribute to health care improvement. The relationship between 
AAA and elevated plasma homocysteine, folic acid, and vitamin 612 remains to be 
established, which this study intends to address.
The aims and objectives of the study were to address the relationship between 
plasma homocysteine, aneurysms, peripheral vascular disease, and vitamins, by means 
of case-control study.
In study 1, patients with abdominal aortic aneurysm (AAA) and age matched 
controls without abdominal aortic aneurysm were selected. Though there can be 
aneurysms anywhere in the arterial tree in the human body, the researcher selected 
abdominal aortic aneurysm because of its clinical importance and significance, the 
ease of an objective assessment of its size and the availability of patients with this 
disorder in the vascular surgical unit at the Royal Glamorgan Hospital. The study 
measured folic acid, vitamin 812 since several studies have shown their inverse 
relationship to plasma homocysteine in the genesis of atherosclerotic vascular 
disorder.
In study 2, the researcher aimed to measure the plasma homocysteine and its 
relationship to peripheral vascular disease (PVD) in comparison to controls who were 
objectively assessed not to suffer from peripheral vascular disease. The aim was to 
examine the possible relationship between plasma homocysteine and peripheral 
vascular disease in the population in Wales, since there has been no study that has 
examined such an association. If the relationship demonstrated in study 2 was similar 
to those reported in the literature, this would confirm that the effect of elevated 
plasma homocysteine on vascular disorder is no different in the Welsh population 
than those shown in studies around the world. This result would act as an additional 
control or benchmark for comparison to the results of study 1. Folic acid and vitamin 
812 were also measured, since several studies have shown their inverse relationship to 





Homocysteine is a sulphur containing amino acid and elevated levels of 
homocysteine are commonly referred to as hyperhomocysteinemia. The normal range 
of fasting plasma homocysteine is 5-15umol/L (Still and McDowell, 1998; Refsum et 
al., 1997). The terms mild, moderate and severe hyperhomocysteinemia refer to 
elevated plasma homocysteine <30umol/L, 30 - lOOumol/L and >100umol/L 
respectively. Even minor elevations of homocysteine have been implicated in the 
pathogenesis of vascular disorders (Boushey et al., 1995). In exercising its effect on 
vascular diseases, elevated levels of homocysteine have been shown to be a major 
independent risk factor (Graham et al., 1997; Boushey et al., 1995; Clarke et al., 
1991). The effect on the arteries can cause atherosclerotic stenotic lesions involving 
the cerebrovascular, cardiovascular and peripheral vascular vessels (Boers et al., 
1985; Brattstrom et al., 1984; Wilcken and Wilcken, 1976). Their respective clinical 
manifestation results in stroke, myocardial infarction or angina and intermittent 
claudication or rest pain. However, if stenosis or narrowing of the arteries represents 
one end of the spectrum of pathological effects of raised homocysteine, aneurysm 
formation or dilatation of the arteries may represent the other end. Whereas, stenotic 
lesions have received much attention in the scientific literature, there has been only 
isolated reported cases of raised homocysteine associated with aneurysm formation 
(Almgren et al., 1978; Colwell et al., 1991; Mohan et al., 1997) and one prospective 
study of raised homocysteine and abdominal aortic aneurysm (AAA) (Brunelli et al., 
2000). Almgren et al. (1978) reported the first case of abdominal aortic aneurysm in a 
35 year-old-man with homocysteinuria. This patient also had symptoms of peripheral
vascular disease. The diagnosis of AAA was confirmed on aortography and AAA was
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repaired surgically. Homocysteinuria was treated with pyridoxine and subsequent test 
for homocysteinuria was negative. Colwell et al. (1991) reported multiple aneurysms 
and hyperhomocysteinemia in a 64-year-old male. On clinical examination he had no 
known risk factors for aneurysm but had mild hypertension. All the laboratory tests 
were also normal for risk factors. Angiogram revealed multiple aneurysms- aortic, 
iliac, femoral and popliteal. Plasma homocysteine level was 39 umol/L. Pathology 
showed moderate intimal thickening, fibroelastosis, and extensive fragmentation and 
degeneration of the tunica media. Moreover, enzyme cystathione p synthetase was 
markedly reduced, thus explaining the basis for elevated plasma homocysteine. The 
patient underwent elective surgical repair of the aneurysms and made an uneventful 
recovery. Mohan et al. (1997) reported an association of hyperhomocysteinemia with 
an 11 cm external iliac aneurysm in a 66-year-old man. The patient had otherwise 
normal peripheral pulses and no evidence of other aneurysmal disease. 
Haematological investigation revealed that the patient had macrocytic anaemia despite 
normal levels of vitamin 812 and folic acid, possibly because the patient was an 
alcoholic. The plasma homocysteine level was 56 umol/L. Pathology showed a 
thickened vascular wall with medial fibrosis, fragmentation of the elastic tissue 
network due to hyaline and mucinoid degeneration and cystic medial change. 
Bacterial and fungal cultures were negative. Genetic testing revealed that the patient 
was heterozygous positive for the MTHFR C667T transition. The patient underwent 
surgical repair of the aneurysm and made an uneventful recovery and was discharged 
home. It is worth noting that this patient had no known risk factors for aneurysms. 
These case reports were the only evidence to suggest elevated plasma homocysteine 
levels in the presence of abdominal aortic aneurysms, until Brunelli et al. (2000) 
demonstrated that patients with AAA had significantly higher levels of homocysteine 
in comparison to control (see section on pathogenesis - aneurysm). AAA is by far the
most important of the aneurysms due to the very high mortality exceeding 80% 
associated with its rupture (Basnyat et al., 1999). The relationship of raised plasma 
homocysteine and abdominal aortic aneurysm therefore remains largely unexplored.
2.2 History and Background
Gibson (1964) and Shimke (1965) first described the correlation between 
hyperhomocysteinemia and vascular diseases in the early sixties on patients with the 
inherited disorder of homocysteinuria. It was the observation that patients suffering 
from homocysteinuria, an autosomal recessive metabolic disorder of raised plasma 
homocysteine, suffered from various vascular disorders that drew attention to the 
causal relationship with homocysteine. McCully (1969) suggested that raised plasma 
homocysteine is involved in the pathogenesis of atherosclerosis. Indeed, homozygous 
(when the 2 alleles, one from the maternal derived chromosome and the other from 
paternal derived chromosome, at a given locus or point along a chromosome are 
identical) patients for a recessive metabolic disorder affecting the plasma 
concentration of homocysteine present frequent life-threatening arterial and venous 
thrombo-embolic events. Marker (1976) conducted an experiment on baboons by 
artificially inducing homocysteinemia. A solution of homocysteine was infused 
continuously by femoral AV shunt throughout a 3-month period. 0.3 gm of 
homocysteine per kg body weight was infused per day (3 gm dissolved in 100 mis of 
0.15 M NaCl solution at the pH 7.4). The homocysteine infusion was given at the rate 
of about 4 ml/hr, which produced a plasma concentration of 0.1-0.2 mM. Silver nitrate 
staining, light and electron microscopic examination of section of the thoracic and 
abdominal aorta, iliac and femoral arteries revealed endothelial vascular injury and
atherosclerosis. Further studies demonstrated that elevated levels of homocysteine
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was a risk factor in the causation of coronary artery (Wilcken and Wilcken, 1976), 
cerebrovascular (Brattstrom et al., 1984) and peripheral vascular diseases (Boers et 
al., 1985). Subsequently, it was demonstrated that the effect of hyperhomocysteinemia 
was independent of other risk factors such as age, gender, lipids, lipoproteins, 
cholesterol, hypertension, diabetes and smoking. (Graham et al., 1997; Boushey et al., 
1995; Clarkeetal., 1991).
With regards to the aneurysm formation and homocysteine, the association was 
first described by Almgren et al. (1978) in a case report of a 35-year old man with 
ruptured AAA. Colwell et al. (1991) reported a case of multiple aneurysms and hyper 
homocysteinemia in a 64-year male suffering with heterozygous homocysteinuria. 
Mohan et al. (1997) reported an isolated external iliac aneurysm associated with 
hyperhomocysteinemia. To date, there is only one published study in the English 
language that has examined the possible relationship of plasma homocysteine and 
AAA (Brunelli et al., 2000). Brunelli et al. (2000) investigated the prevalence of mild 
homocysteinemia in patients with AAA. Their data showed an association between 
the presence of AAA in patients selected for surgical treatment of AAA and elevated 





Figure 1. Structure of Homocysteine
2.3 Chemistry and Metabolism
Homocysteine {HSCI^CHaCHCN^HaJCCV} is a sulphur containing amino acid 
(figure- 1) and is the sum of homocyst(e)ine, homocystine, and the homocysteine- 
cystine mixed disulphides, free and protein bound (Fortin and Genest, 1995). 
Hyperhomocysteinemia is defined as an increased level of fasting homocysteine or 
increased level of homocysteine after a loading dose of methionine. Stryer (1988) 
suggested that homocysteine might be considered as the by-product of the 
demethylation of methionine. The latter process involves the formation of s- 
adenosylmethionine (SAM) which serves as a methyl donor mainly in the synthesis of 
creatine, norepinephrine to form epinephrine, phosphatidyl-ethanolamine to form 
phosphatidyl-choline, cytosine to form 5-methylcytosine as well as several trans- 
membrane proteins.
Remethylation of homocysteine to methionine involves methylation by a 
complex process (Fortin and Genest, 1995) (figure-2). Methylene is donated by serine
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to tetrahydrofolate derived from folic acid, to form 5'10' methylene tetrahydrofolate 
by the enzyme methylene tetrahydrofolate reductase which is then reduced to 
5'methyl tetrahydrofolate with the release of a methyl group, by the enzyme methyl 
tetrahydrofolate reductase (MTHFR). The methyl group thus released is made 
available for remethylation of homocysteine to methionine by the enzyme 
homocysteine methionine methyl transferase (HMMT) using cobalamine (vitamin 
Bi 2 ) as co-factor. Thus, the process of remethylation of homocysteine to methionine is 
dependent on adequate availability of folic acid and vitamins B] 2 . An alternative or 
second pathway of remethylation involves the availability of methyl group from 
betaine forming di-methyl-glycine in the process. This pathway is not dependent on 
folic acid or vitamin B t2 . The third alternative in the homocysteine metabolism is the 
formation of cysteine, via a trans-sulphuration reaction (Fortin and Genest, 1995). 
Homocysteine first forms cystathionine by transfer of beta carbon onto serine, with 
the help of cystathionine-(3-synthetase, a pyridoxal phosphate dependant enzyme 
(PLP) that is a derivative of vitamin Be. Cystathionine is then cleaved to cysteine and 
a-ketobutyric acid, by the enzyme ycystathionase, which is also a PLP dependant 
enzyme. Essentially, homocystine does not appear to have a biologic role, and is 
remethylated to methionine or transulphurated to cysteine. Thus, any fall in 
remethylation or transulphuration of homocysteine, or increased demethylation of 
methionine results in a hyperhomocysteinemic state.
11
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Figure 2. Biochemical pathway of homocysteine metabolism
MTHF= methyl tetra hydro folate, HMMT= homocysteine methionine methyl 
transferase, THF= tetrahydrofolate, SAM = s adenosyl methionine
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2.4 Homocysteine and Peripheral Vascular Disease- Clinical Implications. 
2.4.1 Introduction
Peripheral vascular disease is a common clinical condition. Annual mortality 
from peripheral vascular disease in the U.K. is estimated to be more than 2,500 and 
mortality from vascular disease of arteries and arterioles is estimated to be nearly 
16,000 per annum (Office of Population Censuses and Surveys. 1995).
The natural history of homozygous homocysteinuria due to cystathionine 
synthetase deficiency demonstrates that severe hyperhomocysteinemia is a strong risk 
factor for vascular disease (Mudd et al., 1995; Boers, 1986). Mudd et al., 1985 also 
found that the occurrence of arterial occlusive diseases and thromboembolism in 
young adults is strikingly frequent such that 50% of untreated homozygous 
homocysteinuric patients under the age of 30 years may develop vascular disease. 
Other authors have also concluded that thrombotic and arteriosclerotic complications 
in homocysteinuria suggests that carriers for this condition with slightly elevated 
homocysteine levels might be at increased risk for vascular diseases (Wilcken and 
Dudman, 1989; Wilcken and Wilcken, 1976; McCully, 1969). It has been suggested 
that the risk factor for vascular diseases in the general population is mild hyper 
homocysteinemia. This is due to the more frequent distribution in the population of 
mild defects in methionine metabolism leading to moderately elevated blood 
homocysteine levels (Clarke et al., 1991; Boers et al., 1985). They also concluded that 
heterozygosity for classical homocysteinuria was the basis of mild 
hyperhomocysteinemia seen in vascular patients.
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2.4.2 Homocysteine and Vascular Disease
Reports from two studies based on biochemical and pathological studies in 
homocysteinuric children showed that elevated blood homocysteine may cause 
atherosclerosis (McCully and Wilson, 1975; Mudd et al., 1995). Further studies 
suggested that elevated homocysteine was a risk factor for arterial and venous 
thromboembolism (Clarke et al., 1991; den Heijer et al., 1998). Other authors have 
concluded a similar outcome and reported milder increases in plasma homocysteine 
levels in the presence of vascular diseases specially of large and medium sized 
arteries, such as the coronary arteries, the iliac, femoral, and carotid arteries (Clarke et 
al., 1991; Genest et al., 1990; Coull et al., 1990; Brattstrom et al., 1990; Malinow et 
al., 1989; Brattstrom et al., 1984).
Swift and Shultz (1986) reported that a higher plasma homocysteine value was 
found in high risk groups (people with one or more risk factors such as hypertension, 
hyperlipidemia, smoking, obesity and diabetes) for coronary artery disease compared 
to low risk groups (people with none of the known risk factors). Genest et al. (1990) 
found that patients with 4 or more risk factors had higher homocysteine levels than 
patients with 2 risk factors. Boushey et al. (1995) indicated that elevated fasting levels 
of plasma homocysteine constitute a strong risk for vascular diseases. They calculated 
that for each increase in total homocysteine of 5 ^mol/L (one SD from mean level in 
the normal population) there was an increment of about 40% in relative risk of 
coronary artery disease, a risk which is comparable with the effect of a rise of blood 
cholesterol of 0.5 umol/L. This finding demonstrates comparable strengths of 
cholesterol and homocysteine as a risk factor for vascular diseases. Boushey et al. 
(1995) further suggested that an elevation in homocysteine was an independent graded
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risk factor for arteriosclerotic vascular diseases. The odds ratio for coronary artery 
disease of a 5 |amol/L homocysteine increment was 1.6 for men and 1.8 for women. A 
total of 10% of the population's CAD risk appears attributable to homocysteine. The 
combined (men and women) odds ratio for cerebrovascular diseases was 1.5 and for 
peripheral arterial diseases was 1.8. Elevated homocysteine levels were as strongly 
related to vascular diseases, namely coronary artery disease, cerebrovascular disease, 
and peripheral vascular disease, as cholesterol levels and smoking; hypertension was 
more strongly related to risk than was elevated homocysteine. Fasting and postload 
(oral intake of methionine) elevations in homocysteine had independent effects on risk 
and when present together the net effect was multiplicative (multiple of the fasting 
and postload effects). The relative risk for a subject with an elevated fasting 
homocysteine level was only 1.6 and that for elevated postload level was only 1.5, 
while for a subject with both elevated fasting and postload levels, the relative risk was 
2.5 (Graham et al., 1997). Other authors found that homocysteine concentrations were 
elevated in upto 30% patients with atherosclerosis (Clarke et al., 1991).
Wilcken & Wilcken first demonstrated that abnormally elevated plasma 
cysteine-homocysteine disulphide levels after methionine loading were three times 
more common in patients with CAD than in controls (Wilcken and Wilcken, 1976). In 
CAD the ratio for mean homocysteine of patients to controls varied from 1.2 to 1.3, 
whereas in peripheral and cerebrovascular diseases the ratio ranged from 1.5 to 1.8. 
The ratio of the incidence of hyperhomocysteinemia in patients vs controls ranged 
form 2.6 to 5.3 in CAD and from 2.2. to 9 in PVD and CVD. The authors have not 
shown the statistical significance of these differences though they suggest a more 
pronounced correlation of homocysteinemia with peripheral and cerebrovascular 
arterial diseases than with CAD (Kang et al., 1992). In a further study hyper 
homocysteinemia was found in 41.8% of patients with peripheral and cerebrovascular
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arterial diseases and in 11.9 % of those with CAD (Malinow, 1991). Others have 
shown that moderate and intermediate hyperhomocysteinemia was present in 12- 47% 
of patients with coronary, cerebral and peripheral arterial occlusive diseases despite 
not exhibiting the systemic abnormalities characteristic of homocysteinuria. (Kang et 
al., 1992). Furthermore, the risk of CAD showed a dose dependent response across the 
entire distribution of basal and post-methionine levels of homocysteine and this effect 
was statistically independent of conventional factors for atherosclerosis (Refsum et 
al., 1998; Graham et al., 1997; Arnesen et al., 1995).
The risk of death in men and women with CAD was highly correlated with basal 
levels of homocysteine; mortality estimate for subjects with homocysteine levels 
>15umol/L was 24.7% against 3.8% for homocysteine levels <9umol/L over a 
follow-up period of 4.6 years. In addition, the more markedly elevated fasting 
homocysteine levels were found in patients with dialysis-dependence and end-stage 
renal diseases which may also contribute independently to the excess incidence of 
fatal and non-fatal vascular diseases (Bostom et al., 1997).
2.4.3 Homocysteine as an independent risk factor for vascular diseases
There is evidence that indicates that moderately elevated plasma homocysteine 
level is an independent risk factor in the development of occlusive arterial diseases 
(Pancharuniti et al., 1994; Stampfer et al., 1992; Clarke et al., 1991; Genest et al., 
1990). A further study demonstrated a statistically significant graded increase in 
plasma homocysteine levels is associated with advancing age, lessening degree of 
physical activity, increased smoking, higher cholesterol levels and increased diastolic 
blood pressure (Nygard et al., 1995). Homocysteine, free and protein bound, has been
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shown to be an independent risk factor in selected population such as patients with 
extra cranial carotid disease and ischaemic heart disease (Selhub et al., 1995; Wilcken 
and Wilcken, 1976). Furthermore, the level of homocysteine in vascular diseases was 
independent of total cholesterol, low density lipoprotein or high density lipoprotein 
cholesterol (Pancharuniti et al., 1994; Stampfer et al., 1992; Genest et al., 1990), 
diabetes mellitus (Pancharuniti et al., 1994; Stampfer et al., 1992) smoking 
(Pancharuniti et al., 1994; Stampfer et al., 1992), body mass index (Pancharuniti et al., 
1994; Stampfer et al., 1992), age (Pancharuniti et al., 1994), and high blood pressure 
(Pancharuniti et al., 1994; Stampfer et al., 1992; Genest et al., 1990; Kang et al., 
1986). The odds ratio for CAD was 1.6 and after adjusting for all these risk factors 
was 1.4. There was no significant correlation between plasma homocysteine and 
LDL- cholesterol and protein (r = -0.07, P = 0.51 and r = 0.07, P = 0.47,). Stampfer 
(1992) showed that the relative risk (RR) for myocardial infarction in US physicians 
for the highest 5% vs the bottom 90% of homocysteine levels was 3.1 (95% 
confidence interval, 1.4 to 6.9; P= 0.005). After adjusting for the above risk factors 
the RR was 3.4 (95% confidence interval, 1.3 to 8.8; P = 0.01). There was no 
correlation between plasma homocysteine and HDL-cholesterol, body mass index and 
diabetes (r= -0.07, 0.03, 0.09, P= > 0.05). Renal function impairment had a direct 
relationship to plasma homocysteine not only because excretion is impaired but 
largely because kidney is the site for metabolism of bulk of the plasma homocysteine 
(Quiroga et al., 2001). However, homocysteine remained a risk factor for vascular 
disease after adjustment of serum creatinine as an indicator of renal function (Wu et 
al., 1994). Others (Glueck et al., 1995) have also shown that homocysteine and age 
were positively related to atherosclerotic events. The highest risk of an 
atherosclerotic event was in men and was seen when homocysteine was high and 
high-density lipoprotein was low. After covariance adjustment for age, sex, race,
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Quetelet index (body mass index), LDL, and cholesterol, Glueck et al. (1995), 
observed that subjects with atherosclerotic events had higher mean homocysteine and 
higher cystathionine than those without events. The authors suggested that 
homocysteine may be usefully measured in patients with or without major 
conventional risk factors for atherosclerosis who nevertheless have severe premature 
atherosclerosis that could be due to hyperhomocysteinemia.
Until further evidence emerged (Pancharuniti et al., 1994; Stampfer et al., 1992; 
Genest et al., 1990; Kang et al., 1986) that homocysteine is an independent risk factor 
in the genesis of atherosclerosis, some authors (Mudd et al., 1981) had argued that 
hyperhomocysteinemia had given rise to a plethora of in vitro experiments and 
patholophysiogical hypothesis to explain the dramatic increase in atherosclerotic 
vascular diseases and in thromboembolism observed in patients with the severe inborn 
form of the diseases. They claimed that the epidemiological finding of increased 
homocysteine in patients with premature atherosclerosis had not yet received an 
indisputable explanation for the mechanisms involved. Moreover, they also indicated 
that homocysteinuric obligate heterozygotes, although presenting with high levels of 
plasma homocysteine levels do not have increased incidence of vascular diseases 
(Mudd et al., 1981). However, there were two main limitations of this study. First, 
because the cardiovascular diagnoses were arrived at by the questionnaire method, the 
validity of these diagnoses is subject to more uncertainty than would have been the 
case had direct physical and electrocardiographic examination been possible. Second, 
with a 20% loss in response rate, some unidentified participation bias may have 
possibly been operating. Third, presence of a more subtle interaction between 
homocysteine and diet such as vitamins and protein could not be ascertained because 
the subjects dietary habits were not known. Furthermore, their own data suggested an
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association between elevated homocysteine and haemostatic disorders, and higher 
plasma homocysteine in patients vs controls. Several studies published subsequently 
(discussed in this section earlier) and the meta-analysis by Boushey et al. (1997) it is 
now known that homocysteine is an independent risk factor in the genesis of vascular 
diseases.
2.5 Pathogenesis
2.5.1 Atherosclerosis, endothelial damage, smooth muscle hyperplasia and 
platelet activation
Homocysteine may modulate some aspects of atherogenesis, vascular diseases 
and thrombosis (figure-3). A number of studies reviewed by Boushey et al. (1995) 
have linked elevated plasma homocysteine levels to atherosclerotic vascular diseases 
affecting coronary, carotid and peripheral arteries. Several mechanisms of 
homocysteine induced atherosclerosis have been proposed (McCully, 1969; Ueland et 
al., 1992). These include endothelial dysfunction, smooth muscle cell hyperplasia and 
increased formation of oxidised lipids. Ross et al. (1986) postulated that endothelial 
cell (EC) injury initiated atherosclerosis. High homocysteine levels may cause 
endothelial damage (Matthias et al., 1996; Harker et al., 1983), affect platelet function 
and coagulation factors (Lentz et al., 1996; Harker et al., 1976) and promote LDL 
oxidation (Heinecke et al., 1993). Substances such as lipids and homocysteine 
initiates endothelial injury which promotes platelet adherence to endothelium and 
release of platelet constituents, mainly the epidermal growth factor and the platelet 
derived growth factor (PDGF). These factors induce smooth muscle cells to migrate 
into the tunica intima of the arteries where they replicate to form connective-tissue
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matrix. The connective tissue along with macrophages, cholesterol and lipids and 
calcium deposition form fibrous plaques that causes atherosclerosis in the vessel wall.
Chambers et al. (1999) observed that elevated levels of homocysteine 
concentration are associated with rapid onset endothelial dysfunction, which is 
mediated through oxidant stress mechanism and can be inhibited by antioxidants such 
as vitamin C. Animal experiments and in-vitro studies of cultured endothelial cells 
have given support to the hypothesis that homocysteine in excess induces endothelial 
cell injury and thereby initiates premature atherosclerosis (Harker et al., 1976; De 
Groot et al., 1983; Wall et al., 1980). These studies revealed that cultured endothelial 
cells that are derived from obligate heterozygotes are deficient in cystathionine beta 
synthetase required for homocysteine metabolism and are more susceptible to 
homocysteine mediated injury than normal cells. Harker et al. (1976) chemically 
induced injury in the arteries in baboons as early as 6 days after the beginning of a 
constant intravenous infusion of homocysteine that resulted in focal loss of arterial 
endothelial cells (Harker et al., 1976). The thoracic and abdominal aorta, iliac and 
femoral artery was stained in silver nitrate and viewed under light and electron 
microscope. This revealed that approximately 10% surface area of the endothelium 
was missing. There was also a 50% decrease in platelet survival, which mimicked 
those observed in familial homocysteinuria in man. Several authors have 
demonstrated that atherosclerosis was also common in patients heterozygous for 
homocysteinemia, and in those with high homocysteine levels due to reduced renal 
function, folate and vitamin BH deficiency (Dudman et al., 1993; Stampfer et al., 
1992; Clarke et al., 1991; Genest et al., 1990; Mudd et al., 1995).
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2.5.2 Nitric oxide, Glutathione peroxidase, Lipid peroxidase
Although the mechanism by which hyperhomocysteinemia evokes endothelial 
dysfunction are not well understood it is proposed that this action is mediated by 
impaired production of nitric oxide (Stamler et al., 1993). In vitro studies (Nishinaga et 
al., 1993) showed that initial exposure of cultured endothelial cells to homocysteine 
leads to formation and release of nitric oxide, S-nitrosothiols, and S- 
nitrosohomocysteine, substances with potent vasodilator and platelet inhibition 
properties. However, with continued exposure the oxidative effects of homocysteine 
predominate leading to reduced production or inactivation of nitric oxide (Nishinaga et 
al., 1993; Stamler et al., 1993). Stamler and Slivka (1996) suggested mechanism for 
homocysteine-induced vascular lesions. They include hypersulphation of connective 
tissue proteoglycans, effects on platelet aggregation and survival, an increase in LDL 
and in LDL oxidation, which leads to formation of lipid peroxides, and direct 
endothelial damage by reduced oxygen supply. Homocysteine also inhibits glutathione 
peroxide which contributes to endothelial cellular defence mechanism against oxidative 
stress, by catalysing the reduction of both H2 C>2 and lipid peroxide to less toxic 
alcohols. Stamler et al. (1993) also found that impaired availability of nitric oxide made 












































Figure 3. The role of homocysteine in the pathogenesis of atherosclerosis.
Abbreviations: B 12 , cobalamin; B6 , Pyridoxal phosphate; SAM, S-adenosyl methionine; 
LDL, Low density lipoprotein; HcyT, homocysteine thiolactone; PAPS, Phosphoadenosine 
phosphosulphate; GAG, glycosaminoglycans.
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2.5.3 Hydrogen peroxide (H2 O 2)
Sulphur-containing amino acids such as homocysteine disrupt endothelial cell 
in vitro by a mechanism that involves generation of hydrogen peroxide in a copper 
catalysed reaction that causes auto-oxidation of homocysteine (Wall et al., 1980; 
Starkebaum and Harlan, 1986; Loscalzo, 1996). The H2 O2 induces DNA degradation, 
and inhibits DNA synthesis in endothelial cells in a dose dependant manner 
(Loscalzo, 1996; Blundell et al., 1996) Panganamala et al. (1986) and Saez et al. 
(1982) further confirmed that homocysteine-induced endothelial cell detachment was 
prevented by catalase but not by superoxide dismutase, which would suggest that 
hydrogen peroxide plays a role in mediating injury.
2.5.4 Coagulation Factors- Prostaglandin I2 (PGI2), Thromboxane
Homocysteine induces chemical injury to cultured endothelial cells due to 
modification of arachidonic acid metabolism. It seems that homocysteine participates 
in the generation of hydrogen peroxide, which interacts with the synthesis of arterial 
prostacyclines such as prostaglandin I2 (PGI2) (Starkebaum and Harlan, 1986; Saez et 
al., 1982; Graeber et al., 1982). The effect of homocysteine on PGI2 synthesis seems 
to be dependent on the oxidation of homocysteine and the subsequent generation of 
hydrogen peroxide. Once the production of prostacyclines such as PGI2 is suppressed 
the normal haemostatic balance between it and the increased platelet thromboxane A2 
is lost, which promotes coagulation.
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2.5.5 Tissue Factor
Tissue factor (TF) which has procoagulant activity has been shown to increase 
with elevated levels of homocysteine. Homocysteine increased HUVE (Human 
umbilical vein endothelial) cell tissue function activity in a concentration and time- 
dependent manner, with a seven-fold increase in tissue function activity seen with 
lOmmol/L homocysteine. A higher concentration of homocysteine induced HUVE 
cell cytotoxity with cell retraction and detachment. Moreover, a low concentration of 
homocysteine similar to those found in patients with homocysteinuria, increased TF 
activity by 25 to 100% (Fryer et al., 1993).
2.5.6 Antithrombin III, Factors V, VII, VIII, Factor 8C, Protein-C, 
Thrombomodulin, Tissue Plasminogen
In patients with severe hyperhomocysteinemia reduced levels of factors VII and 
antithrombin III were found (Palareti and Coccheri, 1989). These were correctable by 
administration of folate and pyridoxine (Rodgers and Kane, 1986). Homocysteine was 
also found to reduce protein C activation thus neutralising its protective anticoagulant 
activity (Rodgers and Conn, 1990). Hayashi et al. (1992) suggested that homocysteine 
can be thrombogenic by displacing endothelial cell protein C from thrombomodulin. 
Boushey and Shirley (1995) further supported this view in a quantitative assessment 
of plasma homocysteine as a risk factor for vascular disease. They assessed the effects 
of homocysteine on vascular haemostatic properties and concluded that decreased
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thrombomodulin cell surface expression and inhibition of protein C activation 
probably contributed to the development of thrombosis.
Rodgers et al. (1986) have demonstrated that in terms of thrombotic mechanism 
homocystine activates factor XII and endothelial cell factor V. Harpel et al. (1992) 
observed that homocysteine enhances the binding of an atherogenic lipoprotein to 
fibrin. This occurs at the expense of binding of tissue plasminogen activator to fibrin, 
thus shifting the balance to a coagulant state. Stamler and Slivka (1996) suggested the 
mechanism for hyperhomocysteinemia induced vascular lesions. They are 
hypersulphation of connective tissue proteoglycans, effects on platelet aggregation 
and survival, an increase in LDL and in LDL oxidation, and direct endothelial damage 
by reduced oxygen species (see section on nitric oxide). In the presence of fasting 
hyperhomocysteinemia, factors VIIIc and Von Willebrand were significantly 
increased and thrombin-antithrombin complexes were more elevated (Freyburger et 
al., 1997). Moreover, when post-methionine load homocysteine was increased, 
alterations in fibrinolytic parameters were more pronounced. These alterations were 
associated with significantly higher levels of coagulation activation markers. These 
results demonstrate that in mild hyperhomocysteinemic patients with vascular 
diseases, a trend towards higher haemostatic alterations occur than in 
normohomocysteinemic patients. Thus the pathogenesis involves endothelial damage, 
platelet activation, adhesion and aggregation, smooth muscle proliferation and 
endothelial-leukocyte interaction (Murad et al., 1979; Upchurch et al., 1996; Luscher 
etal, 1996).
The consequences of athero-thrombosis depend on the size and the location of 
the arteries affected. Infarctions may result. Venous thrombosis is also common and 
may occur in vena cava, cerebral sinuses, and/or peripheral veins. Emboli from these
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thrombi may be found in various organs. Some thrombi may be organised and 
recanalised. Intimal hyperplasia and fibrosis may cause the arterial lumen to be 
narrowed. The arterial walls may be dilated, stretched thin, or thickened forming 
aneurysms. Certain nutritional hyperhomocysteinemias may also be associated with 
the development of arteriosclerotic lesions, irrespective of which nutrient is involved, 




The prevalence of abdominal aortic aneurysm is about 4% in the elderly U.K. 
population of >65 years (Office of Population Censuses and Surveys. 1985). 
However, 5000 people in the UK die every year because of AAA and associated 
complications (Office for National Statistics. 1995). Whereas mortality is less than 
6% in patients undergoing elective surgery for AAA, it rises to more than 80% when 
operated on an emergency basis (Campbell et al., 2001). Hence, it is important that 
the risk factors associated with AAA be detected as early as possible. Although the 
association of hypertension (29%), smoking (28%) and previous history of MI and 
angina (16%) with AAA have been well documented (Campbell et al., 2001), the 
biochemical markers of AAA are yet to be evaluated fully. However, certain 
biochemical markers have been implicated in the pathogenesis of vascular diseases 
and aneurysms as detailed below:-
2.6.2 Pathogenesis
2.6.2.1 Hydrogen peroxide
A mechanism has been suggested whereby elevated levels of homocysteine 
could injure endothelial cells through copper catalysed generation of hydrogen 
peroxide (Starkebaum and Harlan, 1986). Homocysteine-induced endothelial cell
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damage has been recognised by some authors (Panganamala et al., 1986; Saez et al., 
1982) . Please see details on hydrogen peroxide in section 2.5.3.
2.6.2.2 Cytokines
Rhode et al. (1999) examined plasma concentration of Interleukin-6 (IL-6), 
(inflammatory cytokine that seems to play a pivotal role in the acute-phase response) 
abdominal aortic diameter and plasma homocysteine among 120 subjects referred for 
transthoracic echocardiogram. In multivariate regression analysis adjusted for age, 
hypertension, diabetes, smoking, ischaemic heart disease and hyperlipidaemia the 
significant correlates of aortic diameter were plasma IL-6 (r = 0.285; P = 0.03), total 
homocysteine (r = 0.241; P = 0.01) and Serum Amyloid A (SAA) (r = 0.274; P = 
0.004). However, unlike other markers of inflammation such as IL-6 and SAA, there 
was no association with C Reactive Protein (CRP) (r = 0.03; P = 0.75). The reason 
for the lack of association between CRP levels and aortic size are unclear, since 
clinical information provided by CRP and SAA are expected to be similar. In this 
cohort, CRP may be insufficiently specific to uncover association between initial 
inflammatory processes and vascular remodelling. Differences in the clearance of 
CRP and SAA could partially explain these findings. In addition, the associations may 
not have been detected because of the small sample size. However, their data support 
a role for chronic inflammation in the progression of asymptomatic aortic disease. 




Frost et al. (1995) proposed the C677T polymorphism in the MTHFR gene as a 
risk factor for vascular disease. The genotype (the genetic information defining the 
phenotype is called the genotype; an observed trait is referred to as phenotype) 
distribution of C677T MTHFR consists of a combination of TT, TC, CC. Tsukahara 
et al. (2000) showed that in the female population the frequency of TT genotype in 
patients with coronary aneurysm was significantly lower than in patients without this 
manifestation. TT genotype may protect female Kawasaki disease patients against 
aneurysm formation and predispose male Kawasaki disease patients to severe 
coronary complications. Miner et al. (1997) opined that individuals homozygous for 
thermolabile variants of MTHFR have elevated plasma homocystine levels. Since it 
arises from a common mutation 677 C to T, this may represent a genetic factor for the 
vascular disease. The mutation occurs in 5,10-MTHFR gene i.e., a C to T substitution 
at nucleotide 677 or valine to alanine substitution which leads to reduced MTHFR 
activity and moderately high plasma homocysteine levels (Miner et al., 1997; Frosst et 
al., 1995).
Homozygous homocysteinuria, the most common genetic disorder of 
transulphuration is associated with elevated plasma concentration of homocysteine 
and homocystine. Multiple clinical abnormalities, life-threatening thromboembolism 
and several instances of vascular aneurysm have also been documented (Colwell et 
al., 1991) (see section 2.2).
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2.6.2.4 Protein C
Rodgers et al. (1990) demonstrated that homocysteine causes endothelial 
dysfunction at several levels by depressing activation of protein C which has an 
antithrombotic activity. Their data suggested that homocysteine-treated vascular 
endothelium induces activation of factor V which in turn reduces endothelial cell 
protein C activation. This leads to coagulation abnormalities and a tendency towards 
thrombosis.
2.6.2.5 Nitric oxide and Lipid peroxides
Stamler et al. (1993) found that homocysteine in vitro, impairs production of 
nitric oxide and promotes lipid peroxidation. McCully et al. (1971, 1994) have shown 
that homocysteine-induced disturbance in oxidative metabolism leads to intimal 
injury, activation of elastase & increased deposition of calcium.
2.6.2.6 Serine elastase
Jourdheuil-Rahmani et al. (1997) noted that homocysteine stimulates the 
synthesis of serine elastase in arterial smooth muscle cells. Campa et al. (1987) found 
a markedly decreased elastin content (8% dry weight of aneurysmal aorta vs 35% dry 
weight of normal aorta) and a high elastinolytic activity in section of the aorta of 
patients of abdominal aortic aneurysm. Bescond et al. (1998) have shown that in 
animal models homocysteine induces elastolysis in arterial media by the activation of 
matrix metalloproteinases-2 (MMP-2).
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2.6.2.7 Thrombomodulin and MTHFR-TT genotype mutation
Brunelli et al. (2000) tried to evaluate homocysteine and thrombomodulin 
plasma levels in patients with AAA. They also evaluated the prevalence of C677T 
MTHFR mutation in patients with AAA and the influence of this mutation on plasma 
homocystine levels. They demonstrated that patients with AAA had significantly 
higher levels of plasma homocysteine in comparison to control. Moreover, the 
subgroup of patients with AAA who did not show evidence of atherosclerosis also 
showed plasma homocysteine levels to be significantly higher, suggesting that 
elevated levels of homocysteine can induce aneurysm formation without actually 
causing atherosclerosis. Furthermore, in patients with AAA, a larger aneurysm size 
was detected in hyperhomocysteinemics than in those with normal plasma 
homocysteine level. They also showed that plasma thrombomodulin levels were 
significantly higher in hyperhomocysteinemics than in normal homocysteinemics. In 
patients with aneurysm a significant correlation was found between homocysteine and 
thrombomodulin. They suggested that homocysteine may interact with the aortic wall 
and induce both elastolysis and cause endothelial damage in these patients. They 
further demonstrated a significant correlation between plasma homocysteine and 
MTHFR TT genotype in patients with AAA.
2.6.2.8 Inhibition of anticoagulation mechanism
Some authors have suggested that the presence of a reduced form of 
homocysteine may induce endothelial injury by inhibiting endothelial anticoagulant 
mechanism (Nishinaga et al., 1993; Starkebaum and Harlan, 1986). Colwell et al.
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(1991) suggested an association between hyperhomocysteinemia and multiple 
aneurysms but said that the exact mechanism in aneurysm formation is not clear.
It is therefore concluded that homocysteine is an independent graded risk factor 
for atherosclerosis in the general population. Atherosclerosis is an arterial disease that 
is recognised to be the chief cause of death in the USA and Europe, the disease 
progresses insidiously for many years before symptoms develop, making it difficult to 
follow the early development of the diseases in individual patients. Identification of 
risk factors by early investigation, and their modification has the potential to modify 
vascular disease progression. Finally, the association between abdominal aortic 
aneurysm and plasma homocysteine is largely unexplored.
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2.7 Peripheral Vascular Disease (PVD)
Peripheral vascular disease, as the name implies is the disease of the arteries of 
the peripheries. In a vast majority of patients the disease involves the lower limbs but 
can also affect the upper extremity. It is commoner in those with risk factors such as 
increasing age (Leng et al., 1996), smoking (Hiatt et al, 1995), hypercholesterolemia 
and hyperlipidemia (Murabito et al., 1997; Ueland and Refsum,1989) hypertension 
and diabetes (UK Prospective Diabetes Study Group, 1998). Since PVD is more 
common in diabetics, it is worth noting that 30% of diabetics will eventually require 
surgical intervention and 10% will require amputation for PVD, besides the fact that 
in diabetic patients amputation rate is seven times higher than in non-diabetics 
(Rosenfield and Isner 1998; McAllister 1976). There is evidence to suggest that 
hyperhomocysteinemia may also be risk factor for peripheral vascular disease 
(Boushey et al., 1995; Ueland and Refsum 1989).
The annual mortality from the vascular disease of the arteries and arterioles is 
estimated to be nearly 16,000 per annum (Office of Population Censuses and Surveys. 
1995) in the U.K., of which 2,500 is from PVD. The rest is attributed to mortality 
from aortic aneurysms, other aneurysms, unspecified atherosclerosis, thrombosis, 
embolism and various arteritis. This does not include figures form ischaemic heart 
disease and cerebrovascular which comprise of over 110, 000 mortality per year.
Since the incidence of the peripheral vascular disease in the lower limbs far 
exceeds that in the upper limb (Haimovici, 1950), it would seem appropriate to imply 
henceforth, the acute limb ischemia (ALI) and chronic limb ischemia (CLI) as the 
disease state in the lower limbs unless stated otherwise.
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2.7.1 Classification
Peripheral vascular disease can be broadly classified into two categories based 
on the clinical presentation:
1 .Acute limb ischemia (ALI) and 
2.Chronic limb ischemia (CLI)
2.7.2 Acute limb ischemia (ALI)
The incidence of this disease tends to occur in about 20 in 25,0000 population 
in the U.K. each year (Office of Population Censuses and Surveys, 1995). It is 
therefore, a relatively uncommon condition. The incidence is however greater in the 
elderly and appears to be increasing.
The causes of the acute limb ischemia can be summarised as follows:
2.7.2.1 Thrombosis






(modified from Beard and Gaines, 1999).
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The commonest cause of ALI is thrombosis at an atherosclerotic arterial stenosis, 
typically of the superficial femoral and popliteal artery. This is found to be commoner 
in the older patients as the incidence of atherosclerosis increases with age (Leng et al., 
1996).
2.7.2.2 Embolism
Embolism can originate from: 







(modified from Beard and Gaines, 1999)
Atrial fibrillation as a result of ischemic heart disease is one of the commonest 
cause of emboli in the western world although in the developing countries rheumatic 
heart disease may still be the commonest cause despite a decline in its incidence. 
Emboli usually lodge at the vessel bifurcation, the commonest site in the lower limb 
being the bifurcation of the common femoral artery. This is due to the decreasing 
diameter of the vessel as the embolus passes down the lumen distally, obstructing at 
the point where the vessel lumen is too narrow for the embolus to squeeze through.
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2.7.2.3 Others






Cystic adventitial disease 
(modified from Beard and Gaines, 1999)
2.7.2.4 Symptoms of acute limb ischemia






Perishing with cold 
(modified from Murie JA 2000)
These symptoms are suggestive of severe ALI with the leg pale and cold with mottled 
appearance, which may initially blanch on pressure. Presence of sensory-motor loss is 
an indication for urgent surgery. Non-blanching and paralysis are signs of irreversible 
vascular injury resulting in limb loss that require amputation.
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Mild to moderate ALI may be result of thrombotic stenosis or an incomplete 
arterial occlusion. There is invariably an element of collateral circulation distal to the 
level of occlusion. Collateral circulation is the leash of smaller vessels around the 
main obstructed vessel, which may reconstitute and unite with the main vessel distal 
to the occlusion.
It is important to distinguish between emboli and a thrombosis as the approach 
to treatment and prognosis differs. Emboli can be caused by cardiac arrhythmia 
usually secondary to ischemic heart disease, with acute onset of severe symptoms, an 
affected pale or white leg with normal pulses in the contralateral leg and 
demonstration of normal arteries on arteriogram. Thrombosis can be caused by 
atheromatous stenosis or aneurysm, usually preceded by history of claudication, less 
acute onset of symptoms, a dusky affected foot on examination with absent or weak 
contralateral pulses, and confirmation of diseased arteries on arteriogram.
2.7.2.5 Management
Once a diagnosis is made on clinical grounds patients should receive 
unfractionated heparin as a bolus intravenous dose of 5,000-10,000 units followed by 
1000 units/hour of intravenous infusion. Adequate analgesics and intravenous fluids 
should be started to prevent propagation of the thrombus. Necessary blood tests such 
as full blood count (FBC), urea electrolyte and creatinine (UEC), blood glucose, 
erythrocyte sedimentation rate (ESR), group and save, and clotting screen should be 
requested along with chest x-ray and electrocardiogram (ECG), to assess and optimise
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the preoperative status of the patient and to have a baseline for postoperative 
monitoring.
The diagnosis should ideally be confirmed on arteriography. If an embolus is 
confirmed, embolectomy should be performed. For a thrombus, thrombolysis 
(dissolving of the clot) can be carried out. The treatment plan is set out in the flow 
chart below in figure-4.
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Figure-4. Flow chart for the management of acute limb ischemia, (modified from 














2.7.3 Chronic Limb Ischemia (CLI)
Chronic limb ischemia is a result of slowly progressive arterial occlusion caused 
by degenerative arterial disease. In a vast majority of the patients with PVD, 
atherosclerosis is the chief cause of the occlusion. 4 - 8% of the population between 
the age of 55 to 74 have chronic limb ischemia with the incidence rising to 16% when 
higher age groups are included (Leng et al., 1996).
2.7.3.1 Symptoms and Signs of CLI
CLI is characterised by intermittent claudication of the calf and/or the thigh 
muscles with absent or weak foot pulses except in conditions such as diabetes where 
the pulses may be palpable. Claudication of the calf, thigh or buttock implies disease 
in the femoropopliteal, ileofemoral and aortoiliac segment of the artery respectively. 
Physical signs may include a loss of hair, shiny, thin and pale skin, muscle wasting, 
unhealthy nails and bruit on auscultation distal to the stenosis or diseased segment in 
the artery.
2.7.3.2 Management
The diagnosis is usually confirmed by measuring the ankle brachial ratio or 
ankle brachial pressure index (ABPI) (see section on ABPI in methodology). This is 
the ratio of the blood pressure measured in the lower limbs to that in the upper limb. 
An ABPI of <0.9 in the presence of symptoms and signs is sufficient to confirm the 
diagnosis (Carter, 1968; Yao, 1969; Yao, 1970). Where pulses may seem normal at 
rest, the chronic ischemia in a limb can be unmasked by means of an Exercise Stress
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Test, where the ABPI in such a limb falls after exercise. The physiological principle 
that explains this phenomenon can be explained as follows. In the presence of 
occlusive lower limb arterial lesions, blood is diverted through high resistance 
collateral vessels or pathways. Although the collateral vessels provide adequate flow 
to the resting extremity with only a modest reduction in ankle pressure i.e. modest fall 
in ABPI, the capacity of these collaterals to increase blood flow during exercise is 
limited. Pressure gradients that are minimal at rest are accentuated by the stress test, 
thus unmasking less severe degree of arterial disease.
Other tests such as Duplex ultrasound scan or Arteriography can be carried out 
when the suitability of intervention has to be decided.
The medical treatment includes modification of risk factors by changing the life 
style. Graded exercise programmes may also bring about improvement in symptoms 
and signs. Failing this, intervention in the form of vascular or endovascular repair is 
carried out.
Endovascular repair consists of angioplasty or stenting and vascular repair 
consists of endarterectomy or bypass using autologous vein or prosthetic grafts.
Critical limb ischemia is an extreme type of CLI, which comprises multiple 
level of arterial disease, an ABPI of < 0.5 and clinically presenting with rest pain in 
the leg with or without ulceration and gangrene. Revascularisation of the limb by 
vascular or endovascular surgical intervention may be needed for limb salvage.
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2.7.4 Abdominal Aortic Aneurysm 
2.7.4.1 Introduction
Aneurysm is a localised dilatation of an artery. When an aneurysm occurs in the 
central artery of the body called the aorta, it is known as an aortic aneurysm. An aortic 
aneurysm located in the abdominal part of the aorta is thus referred to as an abdominal 
aortic aneurysm. The normal diameter of the abdominal aorta in adults is 2 cm in 
either the anterio-posterior or transverse axis. By definition the abdominal aorta is 
said to be aneurysmal if the diameter is 3cm or greater. Others have suggested that an 
increase of 50% in the size of aorta should be classed as an aneurysm since the normal 
diameter of abdominal aorta can vary with age, sex and body mass index (Johnston et 
al., 1991; Lindholt et al., 1997). Abdominal aortic aneurysms usually arise below the 
renal arteries when it is called the infra-renal abdominal aortic aneurysms and are 
amenable to repair. The supra-renal abdominal aortic aneurysms are rare and more 
difficult to repair.
Abdominal aortic aneurysm is prevalent in 5% of adult males above the age of 
65 years (Collin et al., 1988). The incidence of AAA has been steadily increasing over 
the last 30 years due to increased detection and awareness of the disease and also due 
to the increasing number of elderly population (Fowkes et al., 1989). Death from 
AAA ranks thirteenth amongst the common causes of death in the United Kingdom 
(Office of Population Censuses and Surveys. 1995). The total number of deaths from 
all aneurysms (thoracic, abdominal and other aneurysms) in the United Kingdom was 
9252 in the 1993 reported in the Office of Population Censuses and Surveys, 1995. Of 
these, 3883 deaths (2848 men and 1035 women) were from the ruptured abdominal 
aortic aneurysms and 572 from the non-ruptured abdominal aortic aneurysm i.e.
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elective surgical repair. Ultrasound scan of the abdomen is used to screen and detect 
asymptomatic or non-ruptured AAA, and the recommendation for surveillance is bi- 
yearly for aneurysm < 4 cms and yearly for those > 4 cms (Cook and Galland 1996).
2.7.4.2 Aetiology





Connective tissue disorders 
(modified from Wyatt MJ, 1999)
2.7.4.3 Clinical features
Most abdominal aortic aneurysms are asymptomatic and are discovered as an 
incidental finding on routine ultrasound scan (USS) of the abdomen for other reasons, 
during screening for abdominal aortic aneurysm on USS or less commonly during 
routine clinical abdominal examination in patients or on computerised tomography 
scan (CTScan) (Davies et al., 1999).
AAA can cause symptoms from the contained thrombus or from rupture of the 
aneurysm itself. A thromboembolic phenomena related to the AAA presents with ALI 
of the lower limb.
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A rupture must be suspected in a patient with abdominal and or back pain with 
features of hypovolemic shock namely hypotension, tachycardia and pallor. Ruptures 
can be intraperitoneal in which case these signs are more dramatic. Though all these 
signs are present in a retroperitoneal rupture the outcome is better because the rupture 
is contained inside the less yeilding retroperitoneal space.
Most AAA, except for the small ones, can be bimanually palpated as a pulsatile 
and expansile mass in the abdomen above and slightly to the left of the umbilicus. The 
diagnosis is usually confirmed by ultrasound scan of the abdomen. It is widely 
popular as the first investigation of choice because it is safe, widely available, simple 
to use, non-invasive and able to diagnose the presence of an AAA in the vast majority 
of patients with reported sensitivity around 97% in some centres (Smith et al., 1993). 
In doubtful cases however, (CT scan - with or without contrast), a Spiral CT scan or a 
magnetic resonance imaging scan (MRI scan) usually confirms the presence or 
absence of an AAA.
2.7.4.4 Management
There is now a general consensus amongst vascular surgeons that abdominal 
aortic aneurysm of > 5.5 cm should undergo repair following the results of the UK 
Small Aneurysm Trial (1998). Other indications for an AAA repair include:
-An expansion of 1 cm or more/year
-Development of symptoms such as abdominal paiiVback pain or abdominal
tenderness.
44
Repair can be surgical or endovascular. 
Surgical repair
Surgical repair of an AAA is a major operation. This is widely carried out by the 
conventional laparotomy. Some surgeons however, opt for a retroperitoneal approach. 
The principle of the operation involves a midline laparotomy, proximal clamp control 
on the aorta, distal clamps on the common iliac arteries, opening of the aneurysmal 
sac, and inlay of a prosthetic graft, commonly a dacron graft using non-absorbable 
sutures, commonly prolene of size 2/0 or 3/0. The mortality from an elective repair is 
reported to be around 6%, but for ruptured abdominal aortic aneurysm repair the 
mortality has been reported to be around 80% (Galland, 1998; Fowkes et al., 1989; 
Johansson and Swedenborg, 1986; Basnyat et al., 1999).
Endovascular repair
This is still in the trial stage and is carried out in selected centres. The principle 
of this technique involves assessment of the suitability of the aortic aneurysm for 
endovascular repair, access into the aorta via common femoral artery, insertion of a 
predesigned prosthesis (commonly a bifurcated graft) and its lodgement into the aortic 
sac. This is done under radiological control in an elective setting, and is a joint 
endeavour between surgeons and radiologists. Early results suggest that 30-day 
mortality is less than the conventional repair but problems with 'endoleak' and graft 
migration need to be resolved. (Professor Greenhalgh, London, - personal 
communication). These figures for mortality and morbidity will be available once the 
trail is complete.
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Following the results of the UK Small Aneurysm Trial (1998), there is also now 
a greater consensus amongst vascular surgeons that abdominal aortic aneurysm less 
than 5.5 cms should be followed-up by serial ultrasound scans, unless there are other 
indications for operation. The frequencies with which they are followed-up are as 
follows: 
< 4 cm yearly follow up with USS
4 - < 5cm 6 monthly follow up with USS
5 - < 5.5 cm 3 monthly follow up with USS 
5.5 cm or > operate
In summary, PVD and AAA are common in modern society, in the middle-aged 
and the elderly population. Their aetiology is complex and multi-factorial. Prevention 
of disease progression could be achieved by reduction of risk factors. Open surgical 
repair, radiological intervention or a combined approach are the modalities used in the 
treatment of these conditions.
46
2.8 Vitamins and vascular diseases 
2.8.1 Introduction
Serum levels of several vitamins have been shown to affect the level of total 
plasma homocysteine (Woodside et al, 1998; Selhub et al., 1993). Folate and vitamin 
612, are required in the conversion of homocysteine to methionine while vitamin B 6 is 
required in the conversion of homocysteine to cysteine. Vitamin A helps in the 
conversion of homocysteine thiolactone to thioretinamide which in turn is converted 
to sulphate (IV) in the presence of Vitamin C (ascorbic acid). Mild elevation in 




One-carbon tetrahydropteroylglutamate (folates), are involved in many 
biochemical pathways that are necessary for growth, development and homeostasis of 
humans. Unfortunately, humans are unable to synthesise folate de novo. A deficiency 
of this vitamin is associated with neural tube defects and cardiovascular disease 
(Krumdieck et al, 1978).
The active form of folate is pteroylglutamic acid (a substituted ring linked to p- 
aminobenzoic acid linked to glutamic acid by a peptide bond). It is reduced at the 
pteridine ring position 5-,6-,7- and 8- to form tetrahydrofolate (figure-5). Methyl 














Figure 5. Biochemical structure of folate.
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which is the plasma form of the vitamin. Pteroylpolyglutamate, which is the 
pteroylglutamate with the addition of two to seven glutamates in series, is the main 
dietary and intracellular form of folate (Shane and Stokstad, 1985).
The pteroylpolyglutamate has to be hydrolysed before it can be actively 
absorbed into erythrocytes. There are two folate hydrolases in humans, both requiring 
zinc, in the intestinal mucosa located in the brush-border membrane and intracellular 
lysosomes. Clinical studies have shown that the brush-border hydrolase of the 
proximal jejunum is the site where folate is digested (Halsted, 1990). The brush 
border 'conjugase' removes the polyglutamate chain. The monoglutamate form is 
presented to a specific folate receptor on mucosal cells. Over half of natural folates 
are in the form of 5-methyltetrahydrofolate and the rest are converted to this form in 
transit through the mucosal cells or in the first pass through the liver (Scott, 2000). 
The liver is the main site for folate storage and transmethylation with production of 
tetrahydrofolate and methionine. Some pteroylglutamate leaves the liver and 
circulates in plasma and bile. Folate is excreted daily in stool and urine, and has a 
biological half-life of one hundred days (Krumdieck et al., 1978).
Pteroylglutamate is taken up by bone marrow, utilised and circulated in 
erythrocytes as pteroylglutamate. Folate is incorporated into maturing erythrocytes. 
Reticulocytes are released from bone marrow into blood and circulate for one or two 
days, during which time they loose some of their folate. The folate stays in red blood 
cell throughout the cell's life of between 100- 200 days (Berlin et al., 1959). Since red 
blood cells are continually being produced, red blood cell folate could be a reliable 
indicator of folate intake over time.
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Cytosolic folates are mainly pteroylglutamates, whereas plasma and urinary 
folates are pteroylmonoglutamate (Shane, 1990). There appears to be considerable 
variation in the amount and nature of folate-binding proteins in serum (Ratnam and 
Freisheim, 1990). Most of the cytosolic folate-binding proteins are folate-dependant 
enzymes (Ratnam and Freisheim, 1990). Pteroylglutamate is the folate form taken up 
by tissues, and methylates homocysteine, before it is polyglutamated and retained by 
the cells. This implies that cellular concentration of methionine affects cellular 
concentration of folate. Yet, if folic acid is taken, DNA synthesis and cell division 
occur which uses up the limited supply of methionine (protein synthesis), thereby 
reducing the methylation reactions even more. A lack of methylation impairs the 
myelination of nerves and can cause sub-acute combined degeneration of the spinal 
cord (Scott and Weir, 1981). For many one-carbon metabolism enzymes, the glutamyl 
chain length of folate affects its affinity. The one carbon moiety from N5N 10- 
methylenetetrahydrofolate has several roles: the methylene group can be transferred to 
deoxiuridylate to synthesise thymidine; the methylene group could be reduced to a 
methyl group to form pteroylglutamate or the methylene group could be oxidised to a 
formyl group. Since N5N 10-methylenetetrahydrofolate polyglutamate is essential for 
the synthesis of deoxythymidine monophosphate (V) from deoxyuracil 
monophosphate (V) and new cell formation, any folate deficiency will be expressed in 
cells of a high turnover.
In a case study, conducted on himself, Herbert (1962), showed that a folate 
deficient diet produced a decrease in serum folate after three weeks, tissue depletion 
by seven weeks, decreased folate in erythrocytes by seventeen weeks, and 
megaloblastic changes in the bone marrow and anaemia by twenty weeks.
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Jacob et al. (1994) found that in ten healthy men, the plasma homocysteine 
levels rose during folate depletion. In fact, the response of homocysteine to changes in 
folate intake varied amongst individuals from very strong to absent. This illustrated 
people's genetic differences, which is their difference in folate-binding proteins in the 
enterocyte membranes, serum and their tissues.
Folate deficiency can occur because of decreased intake, decreased absorption, 
increased requirement or increased metabolism
2.8.2.2 Vitamin B]2
Vitamin B u is a water-soluble vitamin found in meat, liver and dairy products. 
It is absorbed in the terminal ileum after it is bound to intrinsic factor found in gastric 
mucosa. Diseases of the stomach and those involving the terminal ileum can lead to 
deficiency states of this vitamin.
The structure of vitamin 612 (figure-6) is composed of a central cobalt unit and 
an R-group. The principal R-groups are 5'-deoxyadenosyl (5'deoxyadenosylcobal 
mine), - CH3 (methylcobalmine) and a -OH (hydroxocobalmine). Methylcobalmine is 
the vitamin B[ 2 coenzyme for methionine synthetase (homocysteine to methionine), 
whereas 5'-deoxyadenosylcobalmin is the coenzyme for the mitochondrial 
methylmalonyl-CoA mutase (methylmalonyl CoA to succinyl-CoA).
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Figure 6. Biochemical structure of Vitamin Bn.
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Dietary vitamin Bn is present in proteins in the food, and is liberated by the 
action of gastric enzyme pepsin. Vitamin 812 thus released binds to R proteins, which 
are secreted in saliva, gastric and bile fluids. The alkaline environment of the 
duodenum inhibits pepsin and assists in activation of pancreatic proteases, in 
particular trypsin, which is involved in liberation of vitamin 812 from the R factor. 
Vitamin 812 then binds to intrinsic factor, a glycoprotein secreted by parietal cells of 
the stomach (Grasbeck et al., 1966). The brush-border membrane of terminal ileum 
enterocytes contain a specific receptor for the vitamin 812 - intrinsic factor and 
calcium complex. Within enterocytes it is separated and transferred at the basolateral 
membrane to transcobalamine II and then transferred to the liver (Chanarin et al., 
1978; Rothenberg et al., 1978). The transcobalamine II- Bi 2 complex is taken up into 
tissues by specific receptors (Nexo and Hollenberg, 1980). The vitamin is excreted in 
bile and reabsorbed in the ileum. The body pool of vitamin Bi 2 is 2-3mgs, of which 
80% is in the liver and daily excretion is 1.2 to 1.3 ugm (Hall, 1964).
2.8.3 Clinical Implications
It is known that enzymatic reactions involving folic acid and vitamin B ]2 help in 
the formation of methionine by remethylation of excess homocysteine, thus 
preventing hyperhomocysteinemia and, therefore its associated clinical effects. Thus 
both B !2 and folic acid regulate metabolic pathways catalysed by the enzyme 
methyltetrahydrofolate reductase (MTHFR). Vitamin B 6 helps in the breakdown of 
homocysteine into cysteine in a trans-sulphuration reaction thereby preventing excess 
plasma homocysteine and maintaining normal homocysteine levels.
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A deficiency of folic acid is associated with neural tube defects and megaloblastic 
anaemia and hyperhomocysteinemia associated cardiovascular disease. Deficiency of 
folic acid not uncommonly occurs in alcoholics, the elderly, in those suffering with 
coeliac disease or tropical sprue and in epileptics taking phenytoin preparations. 
Multiple pregnancies, lactation, haemolytic anaemia and leukaemia can all lead to 
deficient folate state (Krumdieck et al., 1978; Halsted, 1990; Scott and Weir, 1981; 
Surtees et al., 1993).
People who are at risk of developing vitamin Bi 2 deficiency are those suffering 
from gastrointestinal disorders, autoimmune disorders that affects parietal cells, type I 
diabetes mellitus, thyroid disorders, and those receiving long-term therapy with 
gastric acid inhibitors (Nilsson-Ehle, 1998). Deficiency of vitamin Bi 2 can lead to 
pernicious anaemia and reduced leukocyte count. However, there is no evidence of 
AAA or PVD in patients with pernicious anaemia or those having terminal ileal 
resections. Vitamin 612 deficiency is also associated with neuropsychiatric disorders 
(Lindenbaum et al., 1988)- parasthesia, weakness, ataxia, dementia and psychosis, and 
subacute combined degeneration of spinal cord (Surtees et al., 1993). Patients with 
vitamin 812 deficiency have elevated plasma homocysteine and cardiovascular 
diseases. Malinow et al. (1996) in their review of 38 studies, found an inverse 
correlation between plasma homocysteine, and serum folic acid, vitamin B i2 and 
vitamin Be.
The European Concerted Action Project study (Graham et al., 1997) studied the 
strength of the relationship and the interaction of plasma homocysteine with other risk 
factors along with serum vitamins- namely folic acid, vitamin B ]2 and vitamin B 6. It
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showed the patients using vitamin preparations experienced protection from vascular 
disease with a relative risk of 0.38 (95% CI 0.2 - 0.7), compared with non-users of 
vitamin supplements. It was also found that red blood cell folate concentration below 
the lowest tenth percentile (<513 r|g/ml) and vitamin B 6 below the twentieth 
percentile (<23.3 r|g/ml) for control subjects were associated with increased risk of 
cardiovascular disease. This was independent of conventional risk factors.
A meta-analysis of trials by Homocysteine Lowering Trialist's Collaboration (1998), 
of serum folic acid, vitamin Bi 2 and vitamin B 6 upon total plasma homocysteine 
concentration, concluded that supplementation with folate reduces plasma total 
homocysteine concentrations, which was particularly noticeable in the highest quintile 
of homocysteine (18.5 u mol/L) and the lowest quintile of serum folate (<6.9 (r|g/ml). 
Malinow et al. (1998) found that daily intake of fortified cereals containing about 500 
ug or more of folic acid in combination with the recommended daily allowance 
(RDA) of other vitamins can reduce plasma homocysteine levels by 14%.
Boushey et al. (1995) calculated that an increase in folic acid intake of 200 ug/day 
reduces homocysteine levels by approximately 4 ug/1. Studies previously have shown 
a fall in homocysteine levels following administration of 650 - 10000 ug of folic acid 
(Dudman et al., 1993; Brattstrom et al., 1984; Brattstrom et al., 1988). A folic acid 
dose of 650ug reduces homocysteine levels by 42% (P<0.001) (Ubbink et al., 1994). 
Other authors have shown that folic acid intake between 200 to 15,000 ug/day can 
lower homocysteine without producing toxicity (Brattstrom, 1996; Guttormsen et al., 
1996). It has been further estimated that a 25% reduction of homocysteine can be 
obtained with 500 to 5,700 ug of folic acid, and if 1 mg/day of vitamin B 12 were
55
added a further 7% reduction of homocysteine was achieved (Homocysteine 
Lowering Trialists' Collaboration 1998). Supplemental vitamin B ]2 has been effective 
in almost 70% of cases, in normalising elevated homocysteine in cases with overt 812 
deficiency (Lindenbaum et al., 1988). In a study using placebo as control, a 
combination of 0.65 nig/day of folic acid, 10 mg/day of vitamin B 6 and 0.4 mg/day of 
812 were effective in normalising moderate hyperhomocysteinemia (Ubbink et al., 
1995). However, there is no additional lowering of homocysteine after 6 weeks of 
supplemental intake of 1000 \j.g of folic acid, 0.4 mg of cobalmine and 12.2 mg of 
pyridoxine if twice these amounts of vitamins are given (Ubbink et al., 1993). 
Dudman et al. (1993) found that folic acid is the more essential amongst the vitamins 
in reducing fasting hyperhomocysteinemia. Cobalmine is also effective in reducing 
homocysteine levels in cases with overt Bi 2 deficiency (Brattstrom et al., 1990).
Pyridoxine intake is effective in reducing elevated homocysteine levels 
following post-methionine intake but not fasting homocysteine levels (Brattstrom and 
Lindgren, 1992; Brattstrom et al., 1990). Other vitamins such as riboflavin in daily 
intakes of 0.6 mg can bring about a modest reduction in plasma homocysteine 
(Shimakawa et al., 1997)
In summary, the evidence strongly identifies an inverse relationship between vitamins 
such as folic acid, vitamin Bi 2 , vitamin B 6 and plasma homocysteine. There is little 
evidence to date that has investigated the relationship between aneurysms, 




Aims of the study
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3.0 Aims of the study and Null hypothesis
This thesis consisted of two studies:
Study 1. The aim of this study was to investigate the relationship between elevated 
plasma homocysteine levels (>15 umol/L), AAA, and serum vitamin Bi 2 and folic 
acid.
Study 2. The aim of this study was to investigate possible relationship between 
elevated plasma homocysteine levels (>15 umol/L), PVD, and serum vitamin 812 and 
folic acid.
3.1 Null Hypothesis (Ho)
Null Hypothesis (1) There are no differences in total plasma homocysteine, vitamin 
B ]2 and folic acid between patients with AAA, PVD, and healthy control.
Null Hypothesis (2) There are no relationships between total plasma homocysteine, 





4.0 Materials and Methods.
4.1 Sample size
Anderson et al. (1992) found the mean plasma total homocysteine concentration 
in healthy subjects was 9.7 ± 2.4 ^mol/1 standard deviation (standard deviation 
24.7%). Rossi et al. (1999) found that the biological coefficient of variation was 8.3% 
and the analytical coefficient of variation was 3.1% for 20 subjects. Similar figures 
were found by Kuo et al. (1997). The critical difference was 24.6%, therefore the 
standardized difference was 24.6/24.7 = 1.00. The number of subjects for the power of 
the test to be 0.9 with a significance level of <0.05 using the nomogram was 30 
(Altman, 1980; Altaian, 1991).
4.2 Number of subjects and the critical variance
Altman, (1980) suggested that the smallest sample size for comparing two 
independent groups when the variable is continuous, could be calculated, assuming 
that the variable has a normal distribution. The total sample size is N, the power of the 
test will be 0.90 (90%) with a significance of 0.05 (5%). The standardized difference 
(SD) is the ratio of the clinically relevant difference to the standard deviation of the 
variable for the study groups.
SD= 6_ = Kx square root of (CVa2 + CVW2 }
8 = critical difference
K = 2.77 for P< 0.05
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C Va - coefficient of analytical variation
CVW = coefficient of within subject variation( biological variation).
s = standard deviation of the changes expected (SD/ X)
CVa =SDa/X
CVW - SDW/X
The study sample size (N) was obtained from the nomogram (Altman 1980). A ruler 
was placed beside the calculated standardised difference value and the hypothetical 
power of the test value. The size of the study was read off when the edge of the ruler 
passed through the 0.05 significance line. The power of the test suggested a sample 
size of 30 patients in each group.
Thirty-six patients with PVD and 36 control subjects and 38 patients with AAA were 
recruited for the study. More than 30 subjects in each groups were selected because 
more than expected number of subjects turned up on the final day of sample 
collection, and presented the opportunity to collect samples on additional subjects in 
case of any eventuality with the 30 samples in each group.
43 Ethical Approval, Informed Consent, Patient Information Sheet and 
Patients Characteristic (Risk factor) sheet
Ethical approval was obtained from the Bro Taff Local Research Ethics 
Committee. The subjects were completely informed about the protocol and study. 
They were given a patient information sheet and informed consent was obtained. 
Another sheet was used to record the characteristic or risk factors for individual 
patients.
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Appendix - 1. Patient Information Sheet
Appendix - 2. Informed Consent
Appendix - 3. Patient Characteristic (Risk Factor) Questionnaire Sheet
4.4 Study design
This was a case-control study.
4.5 Subject selection:
Patients and controls were recruited from the database for ultrasound scan (USS) 
screening programme for AAA. Those with an abdominal aortic diameter of > 3 cm 
were randomly selected for abdominal aortic aneurysm AAA group. Those with a 
normal scan and no symptoms of PVD and ABPI of 1 or greater were selected for 
control group. Patients with clinical symptoms of peripheral vascular disease and 
confirmed ABPI of 0.8 or less and a normal USS of the abdomen were randomly 
selected for peripheral vascular disease group. Thus there were three groups: 1. AAA. 
2. PVD. and 3. Control.
Group 1 - (AAA group) consisted of patients with abdominal aortic aneurysm 
(AP diameter of 3cm or more) diagnosed on ultrasound scan (using Gray-scale B- 
mode images) of the abdomen.
Group 2- (Control group) consisted of individuals free from any known AAA 
which was excluded using an ultrasound abdominal scan, and free of obvious PVD, 
assessed clinically and on the basis of ankle brachial ratio of 1 or greater. These 
individuals were randomly selected from the open access ultrasound scan screening
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programme.
Group3 - (PVD group) consisted of patients with PVD (history of intermittent 
claudication or rest pain and confirmed ABPI of 0.8 or less). These patients also 
underwent USS of the abdomen to exclude any AAA. Thus this group of patients had 
PVD but no clinical or USS evidence of AAA.
4.6 Exclusion criteria
Patients, who had not fasted for 8 hours prior to blood sample withdrawal, those who 
were taking any vitamin supplement, or whose blood sample could not be centrifuged 
for separation of serum within one hour of collection, were excluded from the study.
4.7 Collection of samples
The researcher carried out the blood collection and storage. Approximately 4 ml 
of venous blood were taken from the antecubital vein into a vacutainer tube 
containing EDTA (Beckton-Dickinson, Newbury, Berkshire). The sample was 
immediately transferred to an ice bag and taken to the biochemistry laboratory at the 
Royal Glamorgan Hospital. Within 60 minutes of collection, blood samples were 
placed in a separator and centrifuged at 3,000 revolutions per min for 5 minutes, to 
separate the supernatant serum from the cells. This serum was stored at -80°C prior to 
the analysis of plasma homocysteine concentration.
For vitamin analysis, serum was obtained from another EDTA tube using the same 
centrifugation process. This serum was used to measure Vitamin Bi 2 and folic acid.
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The analysis of the samples were undertaken by biochemists having expertise in this 
field.
4.8 Biochemical Analysis 
4.8.1 Homocysteine
Fasting homocysteine serum levels were analysed using a 'fluorescence 
polarisation immunoassay (FPIA) technique for the quantitative measurement of total 
homocysteine' (IMx system, Axis biochemicals, ASA Ulvenvein, Norway). Plasma 
homocysteine levels > 15 jamol/L were taken as abnormally elevated (Ueland et al., 
1993).
4.8.2 Vitamins
Vitamins 812 and folic acid were measured with an automated immunoassay 
analyser, using a chemiluminescence detection technique (Bayer ACS 180, Newbury, 
Berkshire). The normal range of vitamin 612 was 160 to 350 pg/L and that of folic 
acid was 3.5 to 15 (rig/ml).
In addition, urine specific gravity and haematocrit were ascertained to facilitate 
correction for concentration factor difference between the two groups that could have 
been induced due to overnight fasting.
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4.9 Ultrasound scan (USS) of the abdomen
Ultrasound was performed using a Diasonic DRF 100 real-time scanner 
(Diasonic Sonoton Ltd, Bedford, U.K.), with a 3.5 MHz curved array transducer 
(Aloka SSD-2000, Japan).
All USS were performed by a single vascular technician who had formal 
training in such procedure and had experience of scanning several hundred patients. 
Patients' consent was obtained and the procedure of the USS of the abdomen 
explained, stressing that it is a simple, safe, painless and non-invasive procedure, 
which normally takes about 10 minutes. The patients lay supine on the examination 
bed with the abdomen exposed from the level of xiphisternum to the pubis. Lubricant 
jelly was used to facilitate movement of the USS hand held probe on to the abdomen. 
Gray-scale B-mode images of the abdominal aorta was obtained. The normal diameter 
of the abdominal aorta was taken as 2 cm or less and an aorta was defined to be 
aneurysmal when the anterioposterior (AP) diameter was considered to be 3cm or 
greater (Johnston et al., 1991; Lindholt et al., 1997). Printed records of all the 
aneurysms were obtained. All those with a positive scan were entered into the USS 
surveillance programme to be subsequently followed-up according to the protocol. 
Those who agreed to participate in the study were entered into the AAA group. Those 
with a normal scan were reassured, their details recorded, and 36 subjects amongst 
these who agreed to participate in the study were entered into the control group after 
testing for absence of peripheral vascular status i.e. absence of clinical symptoms of 
PVD and ankle brachial pressure index (ABPI) of 1 or greater. The subjects were 
selected randomly.
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4.10 Ankle brachial pressure index (ABPI)
ABPI was measured using a hand-held Mini Doppler (model no. D 900, 
Huntleigh, Cardiff, U.K.) and a standard sphygmomanometer.
In peripheral arterial disease the signs and symptoms in the lower limbs are due 
to the absolute or relative decrease in the blood pressure or blood flow due to 
obstructions in the proximal aorta or its branches that take care of the peripheral 
circulation. Blood pressure was measured at the brachial artery (brachial pressure) 
medial to the brachialis tendon at the elbow, using a pocket doppler with a hand held 
7 to 10 MHz probe and standard blood pressure cuff measuring 12 cm in width, 
wrapped around the arm above the elbow. Blood pressure at the ankle (ankle pressure) 
was measured using the same cuff around the calf and the doppler targeting the 
posterior tibial artery below the medial malleolus. The anterior tibial artery was not 
used because it is less reliable and more easily affected by calcification in conditions 
such as diabetes. The ABPI is calculated by dividing the systolic pressure at the 
posterior tibial artery by the systolic pressure at the brachial artery. The normal ABPI 
is 1 or greater (Carter, 1968; Yao, 1969; Yao, 1970). Those between 0.9 to <1 are 
considered equivocal, whereas those <0.9 are considered to be indicative of PVD. 
Those with ABPI 0.8 or less were selected randomly into the PVD group. These 
groups of patients had been selected from the out-patients clinic where they were 
referred for specialist vascular assessment.
4.11 Summary and explanation of test
Homocysteine (Hey) is a thiol-containing amino acid produced by the
intracellular demethylation of methionine. Homocysteine is exported into plasma
66
where it circulates, mostly in its oxidized form, bound to plasma proteins as protein- 
Hcy mixed disulphide with albumin (Malinow, 1994). Smaller amounts of reduced 
homocysteine and the disulphide homocysteine (Hcy-SS-Hcy) are present. Total 
homocysteine (THcy) represents the sum of all Hey species found in plasma or serum 
(free plus protein bound).
Homocysteine is metabolised to either cysteine or methionine. A major part of 
homocysteine is remethylated to methionine, mainly by the folate and cobalmine 
dependent enzymes, methylene tetrahydofolate reductase (MTHFR), homocysteine 
methionine methyl transferase (HMMT) and methionine synthetase. In the vitamin B 6 
dependent trans-sulphuration pathway, homocysteine is irreversibly catalysed to 
cysteine with the help of enzyme of cystathione beta synthetase. Homocysteine 
accumulates and is excreted into the blood when these reactions are impaired (Ueland 
andRefsum, 1989).
Severely elevated concentrations of total homocysteine are found in subjects 
with homocysteinuria, a rare genetic disorder of the enzymes involved in the 
metabolism of homocysteine. These patients exhibit mental retardation, early 
arteriosclerosis and arterial and venous thromboembolism (Mudd et al., 1995). Other 
less severe genetic defects, which lead to moderately elevated levels of total 
homocysteine, are also found. Epidemiological research has shown that different 
patient groups might have elevated total homocysteine levels in blood. A meta- 
analysis of 27 studies including more than 4,000 patients estimated that a 5 umol/L 
increase in total homocysteine was associated with an odds ratio of 1.7 for coronary 
artery disease, 1.5 for cerebrovascular disease or the same increase in risk as for a 0.5 
H-mol/L increase in cholesterol (Boushey et al., 1995).
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Patients with chronic renal disease experience an excess morbidity and mortality 
due to arteriosclerotic cerebrovascular disease (CVD). Elevated concentration of total 
homocysteine is a frequently observed finding in the blood of these patients. Although 
they may lack some of the vitamins involved in the metabolism of homocysteine, the 
increased levels of total homocysteine are mainly due to impaired removal of 
homocysteine from the blood by the kidney (Bostom and Lathrop, 1997). Drugs such 
as methotrexate, carbamezapine, phenytoin may elevate levels of homocysteine 
(Ueland et al., 1993).
4.12 Biological principles of the procedure
The homocysteine assay is based on Fluorescence Polarization Immunoassay 
(FPIA) technology.
Bound homocysteine (oxidized form) is reduced to free form. Free 
homocysteine is enzymatically converted to S-adenosyl-L-homocysteine (SAH) as 
outlined below.
4.12.1 Reduction:
Homocysteine and mixed disulphide and protein-bound forms of Hey in the 
sample are reduced to form free Hey by the use of dithiothreitol (DTT). 
Hcy-SS-Hcy(Homocysteine) 




Total free Hey is converted to S-adenosyl-L-homocysteine (SAH) by the use of 
SAH hydrolase and excess adenosine. 
Hey + Adenosine SAH-hydrolase SAH
The IMx homocysteine reagents and sample are added to the FPIA sample 
cartridge and cuvette in the following sequence:
- The probe/electrode assembly delivers the sample, pre-treatment solution, enzyme, 
and FPIA #1 diluent buffer to the predilution well of the sample cartridge.
- The pre-treatment solution reduces homocysteine and mixed disulphide and protein 
bound forms of Hey present in plasma or serum into one chemical form, 
homocysteine.
- The enzyme converts homocysteine to S-adenosyl-L-homocysteine (SAH)
- An aliquot of the pre-dilution mixture, antibody, and FPIA #1, diluent buffer are 
delivered to the cuvette and a background measurement is made by the FPIA 
optical assembly.
- Tracer, FPIA#1 diluent buffer, and a second aliquot of the pre-dilution mixture are 
transferred to the cuvette.
- SAH and labelled fluorescein tracer compete for the sites on the monoclonal 
antibody molecule.




Scientific literatures suggest the normal values of total homocysteine 




The data symmetry (skewness) and kurtosis were obtained using SPSS 
computer software. Data were analysed using non-parametric tests.
4.13.2 Statistical analysis
A one-way analysis of variance (ANOVA) was used to test the significance of 
differences in plasma total homocysteine, vitamin BH and folic acid between the 
AAA, PVD and control groups. Post-hoc comparisons of differences between mean 
values were performed using Scheffe's Confidence Interval test. Data are presented as 
mean ± standard errors of the mean (SE). Differences were considered significant at 
the 95% level (P < 0.05). Pearson correlation was used to examine the relationship 
between plasma homocysteine and Bi 2 , plasma homocysteine and folic acid, and 
plasma homocysteine and the size of AAA, significance level at P < 0.01. Difference 
in the characteristics or risk factors in the control, AAA and the PVD groups were 
analysed using Chi square and Fischer's exact test. All statistical tests were performed 








Hyperhomocysteinemia is a recognised independent risk factor in the genesis of 
atherosclerotic vascular diseases. However very little is known about the relationship 
between homocysteine and abdominal aortic aneurysm (AAA). Vitamins, namely BU 
and folic acid have been implicated in the regulation of plasma homocysteine levels. 
However, there has been no prospective study that has analysed the relationship of 
AAA with plasma homocysteine and serum vitamin levels.
Aims
To study the relationship between plasma homocysteine and AAA in 
conjunction with serum B^ and folic acid levels.
Method
Case control study including 38 AAA patients and 36 controls. Fasting 
homocysteine, BU and folic acid were determined in serum separated within one hour 
of blood collection using a fluorescence polarisation immunoassay technique (FPIA).
Results
26 (68%) of the AAA patients had elevated levels of homocysteine compared to 
2 (6%) in the case control group. The mean homocysteine level in the AAA group 
was 19.4 n.mol/L (95% CI 17.17 - 21.65) and in the control group was 10.9 umol/L 
(95% CI 9.95 - 1 1.88), (P< 0.001). Mean Vitamin B ]2 levels in the AAA and controls 
were 332.1 1 and 414.33 pg./L (SE ± 19.72) respectively (P < 0.004). Mean Folic acid
in the AAA group was 8.02 (SE ±0.71) and in control was 9.8 r|gm/L (SE ± 0.69)
72
respectively (P > 0.05).
Conclusion
This study confirms significantly higher levels of plasma homocysteine in AAA 
patients but lower levels of B^. Use of supplemental vitamins that lower plasma 




Homocysteine biochemistry is complex, with the plasma total homocysteine 
(THcy) being the sum of homocysteine, homocystine, and the homocysteine - cystine 
mixed disulphide, free and protein bound (Fortin and Genest, 1995). It was the 
observation that patients presenting with homocysteinuria, an autosomal recessive 
metabolic disorder leading to raised plasma homocystine, also displayed premature 
vascular disorders that drew attention to the causal relationship between vascular 
disorder and homocystine (McCully, 1969; Gibson, 1964; Shimke, 1965). It was 
subsequently shown in experimental models that intravenous infusion of 
homocysteine caused endothelial vascular injury and atherosclerosis (Marker, 1976). 
Further studies demonstrated that elevated levels of homocysteine were a risk factor 
in the causation of coronary artery (Wilcken and Wilcken, 1976), cerebrovascular 
(Brattstrom et al., 1984) and peripheral vascular diseases (Boers et al., 1985), 
independent of other risk factors such as age, gender, lipids, lipoproteins, cholesterol, 
hypertension and smoking. (Graham et al., 1997; Boushey et al., 1995; Clarke et al., 
1991). There are currently very little data that have examined the possible relationship 
between plasma homocysteine and the development of abdominal aortic aneurysm 
(AAA) (Brunelli et al., 2000) and serum vitamin levels. Therefore, this study was 
designed to investigate possible correlation between THcy, AAA, and serum vitamin 
B 12 and folic acid levels.
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5.3 Materials and Methods. 
5.3.1 Study design
This was a prospective study in which patients were selected into 2 groups.
Group 1- (AAA group) which consisted of patients with AAA (AP diameter 
> 3cms) diagnosed on ultrasound scan (USS) (using Gray-scale B-mode images) of 
the abdomen.
Group 2- (Control group) which consisted of individuals free from any known 
AAA (excluded using an ultrasound abdominal scan), and free of obvious peripheral 
vascular disease, assessed clinically and on the basis of ankle brachial ratio >0.9. 
These individuals were randomly selected from the open access aneurysm USS 
screening programme.
Please see materials and methods, chapter 4, for details of the methodology.
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5.4 Results
There were a total of 74 subjects, 38 in the AAA group with a mean age of 70 
years (range 53- 79) ± SE 0.92, and 36 in the control group with a mean age of 66 
years (range 48- 79) ± SE 1.2.
The characteristics (disease and lifestyle) of patients in the AAA group and the 
control group are summarised in Table-1.
The mean homocysteine concentration for patients in the AAA group was 19.4 
± SE 1.1 umol/L (95% CI 17.17 - 21.65) and for subjects in the control group 10.9 
± SE 0.47 umol/L (95% CI 9.95 - 11.88) (Table-2). The difference between the two 
groups was highly significant (P < 0.001). In the AAA group the mean homocysteine 
levels for patients > 70 years compared to those < 70 years was 19.2 ± SE 0.8 umol/L 
and 19.6 ± SE 0.9 umol/L respectively (P > 0.05). For the control group these values 
were 11.3 ± SD 0.44 vs 10.3 ± SE 0.42 umol/L (P > 0.05). The distribution of 
homocysteine in the AAA and control groups is shown in figures 7. The mean 
homocysteine level in AAA < 4 cm and those > 4cm were 18.8 + SE 0.1.3 umol/L 
and 20.3 ± SE 1.9 umol/L respectively (P > 0.05). There was no correlation between 
the size of AAA and plasma homocysteine level (r = 0.014, P > 0.05) (figure 8).
There were 35 men and 3 women in the AAA group and 21 men and 15 women 
in the control group. The mean homocysteine for males in AAA group was 19 + SE 
0.7 umol/L and for females was 23.4 ± SE 1.1 umol/L (P > 0.05). The mean 
homocysteine for men and women in the control group was 11.5 ± SE 0.6 vs 10.2
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± SE 0.5 umol/L respectively (P > 0.05). These differences for age and sex were not 
significant.
The mean vitamin B, 2 in the AAA group was 332.11 ± SE 16.44 pg/ml and in 
the control group was 414.33 ± SE 19.72 pg/ml. The difference between the two 
groups was highly significant (P < 0.004). The mean folic acid in the AAA group was 
8.02 ± SE 0.71 rig/ml and control group was 9.8 ± SE 0.69 rig/ml (P > 0.05). There 
was no statistically significant difference in the folic acid levels between the two 
groups.
The urinary specific gravity in the AAA group was 1015 ± SE 0.91 and Control 
group was 1018 ± SE 1.42 (P > 0.05). The haematocrit in the AAA group was 43.52 
± SE 0.67 and Control group was 43.82 ± SE 0.68 (P > 0.05). These differences were 
not statistically significant, indicating comparability of the 2 groups in terms of 
hydration status.
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Table-1. Characteristics (disease and lifestyle) of patients in the AAA group 






Cardiac disease (MI, angina)
Stroke
Family history of AAA
Constipation
Cancer











































Table-2. Plasma homocysteine and serum vitamins- B\2 and folic acid, in AAA and
control groups. Values are mean ± SE of the mean
Mean Values AAA Control 'P' value
Homocysteine (umol/L) 19.4+ SE 1.1 10.9 ± SE 0.47 <0.001
VitaminB,2 (pg/ml) 332.11 ± SE 16.44 414.33 ± SE 19.72 < 0.004
Folic acid (rig/ml) 8.02 ± SE 0.71 9.8 ± SE 0.69 =0.1 (ns)
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Figure 7. Plasma homocysteine (THcy) (|J,mol/L) in the 
controls, and patients with AAA. The transverse 
line in the scatterplot represents the median value.
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Figure 8. Plasma homocysteine (THcy) (fo.mol/L) on the Y axis 
and size of the AAA (cm) in individual patients in this group on the 
X axis. There is no correlation (r = 0.014, P > 0.05).
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5.5 Discussion
The primary finding of this study is that plasma homocysteine levels of patients 
with AAA are significantly higher than those of the control group. The importance of 
homocysteine in coronary artery disease, cerebrovascular disease and peripheral 
vascular disease is well documented (Boers et al., 1985; Brattstrom et al., 1984; 
Wilcken and Wilcken, 1976). However, current literature on the role of homocysteine 
in the aetiopathogenesis of AAA is limited (Brunelli et al., 2000; Mohan et al., 1997; 
Colwell et al., 1991; Almgren et al., 1978). 26 of 38 (68%) patients in the AAA group 
had raised plasma homocysteine compared to only 2 of the 34 (6%) patients in the 
control group. Previous authors have found a prevalence of hyperhomocysteinemia in 
40% of patients with peripheral vascular disease (Clarke et al., 1991) and 48% with 
AAA (Brunelli et al., 2000). Present data suggests that there may be a higher 
prevalence of hyperhomocysteinemia in AAA than previously believed. A 6% 
prevalence of hyperhomocysteinemia in the control group is very similar to 5 and 7% 
reported in previous studies (Ueland and Refsum, 1989; McCully, 1992). In the AAA 
group, there was no correlation between the size of the AAA and the levels of 
homocysteine. Though there is evidence that homocysteine is associated with aortic 
atherosclerosis (Konecky et al., 1997) and AAA (Brunelli et al., 2000), it is possible 
that hyperhomocysteinemia initiates the atherosclerosis but once an aneurysm is 
established any subsequent dilatation is more of a mechanical event in relation to the 
blood pressure in the AAA, and with time the AAA progressively dilates.
Four patients in the AAA group had familial history of AAA against none in 
the control group. This raises the question whether the familial nature of AAA is due 
to higher plasma homocysteine, as hyperhomocysteinemia can itself be familial. It is
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well known that patients with homocysteinuria, an autosomal metabolic disorder 
leading to elevated plasma homocysteine, develop premature vascular disease. 
(McCully, 1969; Gibson et al., 1964).
Plasma homocysteine levels have been found to increase with age in some 
(Verhoef et al., 1999; Andersson et al., 1992) but not all previous studies (Kawashiri 
et al., 1999; Currie et al., 1996). This study found no such association when plasma 
homocysteine levels analysed in relation to age, in either the AAA or the control 
group. Similarly, there was no association of plasma homocysteine to sex. The 
homocysteine levels have been shown to be greater in men than women by most 
authors (Lupattelli et al., 1999; Cheng et al., 1997; Selhub et al., 1999) but some have 
shown no difference or marginally higher homocysteine levels in women than men 
(Jacobsen et al., 1989; Quiroga et al., 2001).
It is known that enzymatic reactions involving folic acid and vitamin BU help in 
the formation of methionine by remethylation of excess homocysteine, thus 
preventing hyperhomocysteinemia. Vitamin Be assists in the breakdown of excess 
homocysteine into cysteine in an irreversible trans-sulphuration reaction and thus 
maintains normal homocysteine levels. Previous studies have examined the 
relationship between folic acid, 612 and their influence on the homocysteine levels 
(Chambers et al., 2000; Koehler et al., 1997; Selhub et al., 1999; Koehler et al., 1996) 
These studies have shown that hyperhomocysteinemia is associated with deficiencies 
of vitamin 812 and folate levels. The strongest inverse correlate for patients with 
coronary disease being between homocysteine and folate (Temple et al., 2000; 
Verhoef et al., 1996; Clarke and Armitage, 2000).
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These data have shown that the mean vitamin 612 levels were significantly 
higher in the AAA group than the control group. Although the mean folic acid levels 
were greater in AAA in comparison to control this failed to reach statistical 
significance. Present data suggests that the homocysteine levels are more susceptible 
to changes in vitamin B ]2 as opposed to folic acid levels although, previous studies 
have shown low folate deficiency may be more important than vitamin B ]2 deficiency 
in influencing the plasma homocysteine levels and vascular diseases (Temple et al., 
2000; Verhoef et al., 1996). Vitamin B6 was not measured in the study because the 
Homocysteine Lowering Trialist's Collaboration, (1998), showed that supplemental 
doses of vitamin B 6 does not confer any additional protection unlike folic acid and 
vitamin 612.
In conclusion, this study demonstrates a significantly higher level of plasma 
homocysteine but lower level of vitamin 612 in the AAA group in comparison to the 
control group. In order to confirm the relationship, long-term population studies will 
be required to establish whether patients at risk of AAA can be prevented from 








Elevated levels of plasma homocysteine is a recognised independent risk factor 
in the genesis of atherosclerotic diseases. Previous studies have shown association 
between hyperhomocysteinemia and vascular diseases. However, some authors have 
shown no such associations. Until large scale randomised controlled trials to study 
plasma homocysteinemia in patients with PVD vs control subjects are undertaken and 
results known some degree of controversy may remain with regards to correlation 
between homocysteine and peripheral vascular. Vitamins namely Bi 2 and folic acid 
are known to be involved in the metabolism and regulation of plasma homocysteine 
levels.
Aims
To study the relationship between plasma homocysteine and peripheral vascular 
disease in conjunction with serum vitamin levels i.e. 812 and folic acid.
Method
Case-control study with age matched control group. Fasting homocysteine and 
serum vitamin levels were analysed using FPIA. Serum was separated within one hour 
of blood collection from antecubital venous puncture into an EDTA primed tube, from 
36 PVD patients and 36 case controls.
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Results
Twenty-six (72%) of the PVD patients had elevated levels of homocysteine 
compared with 2 (6%) in the control group. The mean homocysteine level in the PVD 
group was 18.4 ± SE 0.99 umol/L (95% CI 16.32 - 20.35) and in the control group 
was 10.9 ± SE 0.47 umol/L (95% CI 9.95 - 11.88), (P< 0.001). Mean Vitamin B 12 in 
the PVD and control groups was 320.47 ± SE 16.81 and 414.33 ± SE 19.72 pg/L 
respectively (P < 0.004). Mean folic acid in the PVD was 7.84 + SE 0.81 and in 
control was 9.8 ± SE 0.69 rig/L respectively (P > 0.05).
Interestingly, there was an inverse relationship between plasma homocysteine 
levels and serum Bn (P=0.000) (r= -0.42) as well as plasma homocysteine and folic 
acid (P= 0.001) (r= -0.32) (Pearson correlation, significance taken at P < 0.01), when 
all the 110 patients (38 AAA, 38 control and 36 PVD) were taken into account.
Conclusion
This study confirms significantly higher levels of plasma homocysteine in PVD 
patients but lower levels of 612- Use of supplemental vitamins that should lower 
plasma homocysteine may modify vascular disease progression and clinical trials in 
this direction are warranted.
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6.2 Introduction
Studies have demonstrated that elevated levels of homocysteine is a risk factor 
in the causation of coronary artery (Wilcken and Wilcken, 1976), cerebrovascular 
(Brattstrom et al., 1984) and peripheral vascular diseases (Boers et al., 1985), 
independent of other risk factors such as age, gender, lipids, lipoproteins, cholesterol, 
hypertension and smoking (Graham et al., 1997; Boushey et al., 1995; Clarke et al., 
1991). However, some authors (Mudd et al., 1985) have shown no such associations 
though they have found it difficult to attribute any obvious reason for this. Despite 
several studies on plasma homocysteinemia and PVD, some degree of controversy 
remains about the association of homocysteine and peripheral vascular diseases. 
Vitamins, namely 812 and folic acid have been implicated in the metabolism and 
regulation of plasma homocysteine levels.
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6.3 Aim
The aim of this study was to investigate the relationship between elevated 
plasma homocysteine levels (>15 (amol/L), serum vitamin B 12 and folic acid, and 
PVD.
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6.4 Materials and Methods
6.4.1 Study design
This was a case-control study in which patients were selected into 2 groups.
Group 1- which consisted of patients with PVD (history of intermittent claudication or 
rest pain and confirmed ankle brachial ratio of < 0.9).
Group 2- was the control group which consisted of individuals free from any obvious 
peripheral vascular diseases, assessed clinically and confirmed to have an ankle 
brachial ratio of >9.
Please see materials and methods, chapter 3, for details of the methodology.
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6-5 Results
The characteristics or the risk factors of patients in the PVD group and the 
control group are as shown in table-3.
There was a total of 72 patients, 36 in the PVD group, mean age 65.4 ± SE 1.42 
(range 45- 78), and 36 in the control group, mean age 66 ± SE 0.77 (range 48- 79). 
The mean total homocysteine concentration for patients in the PVD group was 18.4 
± SE 0.99 umol/L (95% CI 17.16.3 - 20.35) and for patients in the control group 10.9 
± SE 0.47 umol/L (95% CI 9.95 - 11.88) (table-4). The difference in the two groups 
was highly significant (P < 0.001). The plasma levels of homocysteine reached for 
individual patients in the PVD and the control groups are shown in figure 9.
In the PVD group the mean homocysteine levels for patients < 70 years vs > 70 
years was 17.63 ± SE 0.83 umol/L and 20.8 ± SE 1.12 umol/L respectively (P > 
0.05). For the control group these values were 11.3 ± SE 0.49 vs 10.3 ± SE 0.44 
umol/L (P > 0.05).
There were 28 males and 8 females in the PVD group and 21 males and 15 
females in the control group. The mean homocysteine for males in PVD group was 
18.9 ± SE 0.99 umol/L and for females was 17.7 ± SE 0.89 umol/L (P > 0.05). The 
mean homocysteine for males vs females in the control group was 11.5 ± SE 0.48 
umol/L vs 10.2 ± SE 0.43 umol/L (P > 0.05).
The urinary specific gravity in PVD group was 10.17 and that in the control was
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control 10.18(P > 0.05). The packed cell volume or the haematocrit in the PVD group 
was 43.5 and in the control group was 43.8 (P > 0.05).
Mean vitamin B ]2 in the PVD group was 320.47 ± SE 16.81 pg/ml and in the 
control group was 414.33 ± SE 19.72 pg/ml. The difference between the two groups 
was highly significant (P < 0.004).
Mean folic acid in the PVD group was 7.84 ± SE rig/ml (standard error 0.81) 
(range 6.2 to 9.5) and Control was 9.8 ± SE rig/ml (standard error 0.69) (range 8.4 to 
11.2) (P > 0.05). (The normal reference range for folic acid was 3.2 to 15 rig/ml).
Interestingly, this study found an inverse relationship between plasma 
homocysteine levels and serum Bi 2 (r = - 0.42, P=0.000) as well as plasma 
homocysteine and serum folic acid (r = - 0.32, P= 0.001) (Pearson correlation, 
significance taken at P < 0.01), when all the 110 patients (38 AAA, 36 control and 36 
PVD) were taken into account (Table-5). This may be explained by the fact that the 
lower levels of folic acid in the AAA and the PVD group in comparison to the control 
group, failed to reached statistical significance (P= 0.1) due to smaller sample size. 
However, in the presence of a bigger sample this difference became more apparent 
and did reach the statistical significance. There was no difference in the plasma 
homocysteine levels in the AAA (19.4 + SE 1.1 umol/L) and the PVD group (18.4 
± SE 1.0 umol/L) (P - 1) nor were there any difference in the AAA and the PVD 
groups for serum vitamin B )2 (332 ± SE 16.44 pg/L vs 320 ± SE 16.81 pg/L) and 
folic acid levels 8.02 ± SE 0.71 r|g/ml and 7.84 ± SE 0.81 r|g/ml (P = 1). However, 
there were striking similarity in the distribution of homocysteine levels in the AAA
and PVD groups in comparison to controls (figure 10).
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Table-3. Characteristics (disease and lifestyle) of patients in the PVD group and the control 


















































Table-4. Plasma homocysteine and serum vitamins- 612 and folic acid, in PVD and
control groups. Values are mean ± SE of the mean
Mean Values PVD Control 'P' value
Homocysteine (|amol/L) 18.4± SE 1.4 10.9± SE 0.47 <X001
Vitamin B 12 (pg/ml) 320.47 ± SE 16.81 414.33 ± SE 19.72 < 0.004
Folic acid (rig/ml) 7.84 ± SE0.81 9.8 ± SE 0.69 =0.1
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Figure 9. Plasma bomocysteine (THcy) (fimol/L) in the 
controls and patients with PVD. The transverse 
line in the scatterplot represents the median value.
95







Figure 10. Plasma homocysteine (THcy) (|j.mol/L) in the 
controls, and patients with AAA and PVB. The transverse 
line in the scatterplot represents the median value.
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Table-5. The inverse relationship between plasma homocysteine and serum vitamins- 














































Correlation is significant at the 0.01 level (2-tailed).
Sig. = significance




The mean level of homocysteine in-patients with PVD was 18.4 umol/L (range 
10.7 to 38.31) and that in the control was 10.9umol/L (range 6.8 to 18). This 
difference between the two groups was highly significant (P <0.001). Most authors 
have shown a positive correlation between elevated homocysteine and PVD (Graham 
et al., 1997; Malinow et al., 1989; van den Berg et al., 1996) although some authors 
have found no correlation (Valentine et al., 1996; Mudd et al., 1981; Bunout et al., 
2000). They have suggested smaller sample size, validity of their diagnosis for the 
vascular disease, and lack of information about the protein and vitamin intakes. 
Moreover, 26 of the 36 (72%) patients in the PVD group had raised plasma 
homocysteine compared to only 2 of the 34 (6%) patients in the control group. 
Previous authors have found a prevalence of hyperhomocysteinemia in 40% patients 
with vascular disease (Clarke et al., 1991) and 48% in patients suffering from AAA 
(Brunelli et al., 2000). These data suggest that there is a higher prevalence of 
hyperhomocysteinemia in PVD than previously reported. However, a 6% prevalence 
of hyperhomocysteinemia in control population is very similar to 5 to 7% reported 
earlier (McCully, 1969; Ueland and Refsum, 1989). The maximum concentration of 
plasma homocysteine in patients having PVD was 38umol/L, which is more than 
twice the highest value in the control group. These data support a strong association 
between elevated homocysteine and PVD. Moreover, any influence of the other risk 
factors for PVD in this study should be regarded as minimal, since the difference in 
the prevalence of risk factors in the PVD and the control groups, were not statistically
significant (table-3).
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Homocysteine, PVD, age and sex
Plasma homocysteine levels with reference to vascular disease have been found 
to increase with age in some (Verhoef et al., 1999; Andersson et al., 1992) but not all 
the previous studies (Kawashiri et al., 1999; Currie et al., 1996). There was no such 
association when plasma homocysteine levels in the PVD group for patients < 70 
years was compared with those >70years. The same was true for patients < 70 years 
or older vs >70 years in the control group. The mean homocysteine levels in men was 
18.9 i^mol/L in comparison to females 17.7 [imol/L (P>0.05). These data do not 
support the findings of previous authors who have demonstrated greater plasma 
homocysteine levels in men than women with vascular diseases (Lupattelli et al., 
1999; Cheng et al., 1997; Selhub et al., 1999) but some authors have shown no 
difference or marginally higher homocysteine levels in women than men (Jacobsen et 
al., 1989; Quiroga et al., 2001). There were more men than women in the PVD group 
in this study in keeping with that previously reported (Leng et al., 2000), but the 
researcher cannot explain as to why the number of women is very small in 
comparison to the number of men, since they were selected at random.
Homocysteine, PVD and vitamins
Some authors have shown a direct relationship between plasma homocysteine 
and peripheral vascular disease, and an inverse relationship between homocysteine 
and vitamins Bi 2 and folic acid, (Rassoul et al., 2000; Weiss et al., 1999) but this 
finding has not been consistently demonstrated (Cheng et al., 1997; Bunout et al., 
2000). Previous researchers have studied vitamins- folic acid, 812 and Be intake and 
demonstrated an inverse relationship with plasma homocysteine levels (Chambers et
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al., 2000; Koehler et al., 1997; Selhub et al., 1999; Koehler et al., 1996). It is known 
that enzymatic reactions involving folic acid and vitamin B, 2 helps in the formation of 
methionine by remethylation of excess homocysteine, thus preventing 
hyperhomocysteinemia. Vitamin B6 assists in the breakdown of excess homocysteine 
into cysteine in an irreversible trans-sulphuration reaction and thus maintains normal 
homocysteine levels. This study ascertained vitamin B, 2 and folic acid because these 
vitamins have demonstrated a greater homocysteine lowering effect than vitamin B6 
(Clarke and Armitage, 2000; McKinley, 2000). The mean vitamin B 12 levels of 
414.33 pg/ml (SE 19.72) in the control group were significantly higher than that of 
320.47 pg/ml (SE 16.81) in the PVD group (PO.004). There was no statistically 
significant difference between the mean folic acid levels of 9.8 r|g/ml in the control 
group and 7.84 r)g/ml in the PVD. Previous studies have shown that serum folic acid 
bear stronger inverse relationship with plasma homocysteine and vascular disease 
than vitamin Bi 2 (Temple et al., 2000; Verhoef et al., 1996). However, these data 
suggest that homocysteine levels are more susceptible to changes in vitamin B] 2 levels 
than folic acid levels in patients with PVD.
In conjunction with previous investigations these data would conclude that there 
is a positive correlation of PVD and plasma homocysteine with lower vitamin levels. 
These data are endorsed by Rassoul et al. (2000) and Weiss et al. (1999). 
Supplemental doses of vitamin B] 2 and folic acid may influence the homocysteine 
levels as a modifiable risk factor if large randomised controlled trials were to be used 
to study this effect. Therefore, long term follow-up of vascular disease such as PVD 
with supplemental vitamins that could demonstrate arrest of disease progression will 
be required. Such studies will eventually establish the role of hyperhomocysteinemia 
in the genesis of PVD and its prevention by use of prophylactic vitamins.
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6-7 Recommendation for future research
These data have shown that there is a positive correlation between elevated total 
plasma homocysteine concentration and abdominal aortic aneurysm and peripheral 
vascular disease. These data have also demonstrated that there is an inverse 
correlation between total plasma homocysteine concentration and serum folic acid and 
vitamin Bi 2 , and the levels of serum vitamin B 12 are significantly lower in the 
abdominal aneurysm and peripheral vascular disease groups in comparison to the 
control group.
Selected supplemental vitamins such as folic acid and vitamin Bi 2 in therapeutic doses 
given on a daily basis to patients with abdominal aortic aneurysm and peripheral 
vascular disease may possibly lower the total plasma homocysteine concentration. 
Patients with abdominal aortic aneurysm and peripheral vascular disease will need to 
be randomised into the experimental group scheduled to receive selected vitamins 
against control group randomised scheduled not to receive any supplemental vitamins. 
Serial fasting plasma homocysteine will be measured at the beginning of the study and 
thereafter at 1, 3, 6 and 12 monthly intervals. A significant fall in the fasting total 
plasma homocysteine concentration will establish the homocysteine lowering effect of 
folic acid and vitamin Bi 2 . Whether the lower plasma homocysteine will in turn arrest 
or slow disease progression in patients with abdominal aortic aneurysm and peripheral 
vascular disease will need to be studied. This can be achieved by comparing the 
growth rate of aneurysm in experimental group (receiving supplemental vitamins) and 
control group (not receiving any supplemental vitamins) with abdominal aortic 





It is known that an excess of or a lack of certain chemicals within the blood may 
damage the arteries (blood vessels) leading to a wide variety of problems such as 
stroke, heart attacks and gangrene. We are interested in the role these substance called 
homocysteine and vitamins.
We would be grateful if you could help us in our investigation by providing us 
with a sample of your blood, which we would use to measure the levels of these 
substances. All these tests could be performed during one of your routine visits to the 
out-patient department or on the ward if you were an in-patient.
It is hoped that the information learnt from this study will improve our 
knowledge of the mechanisms will lead to diseases of the arteries.
It is important for you to know that your participation in this study is entirely 
voluntary and you have the right to withdraw from the study at any time without it 
affecting your current or future care. Also, the results of your tests will be kept 
confidential.
If you have any further questions please do not hesitate to ask us. 
Thankyou for your co-operation.
Mr. M.H.Lewis Mr. A.A.Warsi 
Consultant Vascular Surgeon Surgical Research Fellow





I ............................................ Date of birth..................................
Address.............................................................................................
do hereby, consent to give venous blood, from my arm (right or left),
approximately 10 mis in amount for measurement of homocysteine and vitamins
for the purpose of research. I confirm that the procedure has been explained to
me.
However, I am aware that I have the right to refuse, and if I choose to do so, it









Size of Abdominal aorta (cms) 
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